



http://www.e-journals.net



ISSN: 0973-4945; CODEN ECJHAO
E-Journal of Chemistry
Vol. 4, No. 3, pp. 320-342, July 2007

Synthesis, Characterization and Pharmacological Activities of 3,6-Disubstituted-1,2,4-triazolo [3,4-*b*]-1,3,4-thiadiazoles and their Dihydro Analogues

VINOD MATHEW*, J. KESHAVAYYA and V. P. VAIDYA

*Dept. of Pharmaceutical Chemistry,
Acharya & B. M. Reddy College of Pharmacy,
Bangalore-560090, Karnataka, India.

Department of Studies in Chemistry, Kuvempu University,
Jnana Sahayadri, Shankaraghatta- 577451, Shimoga, Karnataka, India.

Received 16 November 2006; Accepted 16 December 2006

Abstract: 4-Amino-5-aryl/heteroaryl substituted-3-mercapto-1,2,4-triazoles 3(a-d) were prepared from the corresponding aromatic carboxylic acids through a multi-step sequence. Compounds 3(a-d) were made to react with various aromatic/hetero aromatic acids and hetero aromatic aldehydes to give 3,6-disubstituted-1,2,4-triazolo [3,4-*b*]-1,3,4-thiadiazoles and 3,6-disubstituted-5,6-dihydro-1,2,4-triazolo [3,4-*b*]-1,3,4-thiadiazoles respectively. Elemental analysis, IR, ¹H NMR and mass spectral data elucidated the structures of all newly synthesized compounds. Synthesized compounds are studied for their antibacterial, antifungal, anti-inflammatory and analgesic activities. Some of the tested compounds showed significant pharmacological activities.


Keywords: Triazoles, Triazolothiadiazoles, Dihydro triazolothiadiazoles, Pharmacological activities.


Introduction

1,2,4-Triazole and 1,3,4-thiadiazoles represent one of the most biologically active classes of compounds, possessing a wide spectrum of activities¹⁻⁵. Various substituted 1,2,4-triazolo [3,4-*b*]-1,3,4-thiadiazoles and their dihydro analogues are associated with diverse pharmacological activities such as antimicrobial⁶, antibacterial⁷, antitubercular⁸, anti-inflammatory⁹⁻¹⁰, antifungal¹¹ *etc.* A triazolo thiadiazole system may be viewed as a cyclic

analogue of two very important components thiosemicarbazide¹² and biguanide¹³, which often display diverse biological activities. Prompted by these observations, as part of our research program aimed at developing new biologically active nitrogen and sulphur containing heterocycles, we report the synthesis of some new 3,6-disubstituted-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazoles (Scheme 2) and their 5,6-dihydro analogues (Scheme 3). 4-Amino-3-aryl/aralkyl/heteroaryl substituted-5-mercapto-1,2,4-triazole 3(a-d) were prepared using the method¹⁴ (Scheme 1). The structures of the intermediate triazole derivatives were based on their elemental analysis and other spectral data.

Condensation of the triazoles 3 (a-d) with aromatic acids in the presence of phosphorous oxychloride (Scheme 2) produced a series of triazolo thiadiazoles (4-16); while its condensation with hetero aromatic aldehydes (Scheme 3) afforded a series of 5,6-dihydro triazolo thiadiazoles (17-20). The structure assigned to compounds was substantiated by their analytical and other spectral data.





Scheme 3

Experimental

Thin layer chromatography was used to access the completion of the reaction and purity of the compounds synthesized. Melting points were taken in open glass capillary tubes using thiels tube containing liquid paraffin and are uncorrected. IR spectra in KBr were recorded on a Shimadzu-8400 FTIR spectrophotometer, ^1H NMR spectra were recorded on Bruker spectrophotometer (400MHz) in $\text{DMSO-d}_6/\text{CDCl}_3$ using TMS as an internal standard (chemical shifts are expressed in δ ppm), mass spectra were recorded in Finnigan MAT 8230 mass spectrophotometer and elemental analysis were recorded on Thermo Finnigan FLASH EA 1112 CHNS analyser. The purity of the compounds were checked on silica gel-G coated plates by using ethyl acetate and petroleum ether (1:1) as the eluent and observed in UV light. All the synthesized compounds gave satisfactory elemental analyses.

General procedure for the preparation of Aryl hydrazide. (1)

To the methyl/ethyl esters of substituted aromatic acids (0.1 mol), hydrazine hydrate (0.1mol) was added and refluxed the solution for 30 min. 20 mL of ethanol was added to the refluxing mixture as a solvent in order to homogenize solution. The resulting mixture was further allowed to reflux for 6 h. Excess ethanol was distilled out and the contents were allowed to cool. The crystals formed was filtered, washed thoroughly with water and dried. The completion of the reaction was monitored on TLC by using silica gel-G coated plates by using ethyl acetate and petroleum ether (1:1) as the eluent and observed under UV light.

General procedure for the preparation of 2-aryl substituted-5-mercapto-1,3,4-oxadiazole (2)

To a solution of **1** (0.1 mol) in ethanol (30 mL), KOH (0.1 mol) in absolute ethanol (50 mL) and CS₂ (0.2 mol) were added and refluxed for about 5 h till evolution of hydrogen sulfide was ceased. The reaction mixture was cooled at room temperature and diluted with water. On acidification with dilute hydrochloric acid, the required oxadiazoles was precipitated. It was filtered, thoroughly washed with cold water and recrystallised from ethanol.

General procedure for the preparation of 3-substituted-4-amino-5-mercapto-1,2,4-triazole.3 (a-d)

A mixture of **2** (0.1 mol) and hydrazine hydrate (0.1 mol) in dry pyridine (15 mL) was refluxed for about 4 h. The reaction mixture was cooled at room temperature and was neutralized with dilute hydrochloric acid. The solid obtained was filtered, thoroughly washed with cold water and recrystallised from ethanol.

4-Amino-3- (3,4-dimethoxy phenyl) -5- mercapto-1,2,4-triazole.(3a)

Yield: 60%; m.p: 212 °C; IR (KBr) ν (cm⁻¹) : 3291 (NH stretching), 1613 (C=N stretching); 3130 (aromatic CH stretching), 2586 (SH), 2934, 2840 (methyl CH stretch), 1269 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 1284 (N-N=C), 1582, 1552, 1479 (C=C ring stretching); ¹H NMR δ (ppm): 13.8 (s, 1H, SH), 7.1 (d, 1H, C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.7 (d, 1H, C-6 of Ar), 5.78 (s, 2H, NH₂), 3.82 (s, 6H, OCH₃); MS m/z : 252 M⁺; Anal. Calcd. (%) for C₁₀H₁₂N₄O₂S: C, 47.61; H, 4.79; N, 22.21; S, 12.71. Found: C, 47.69; H, 4.81; N, 22.16; S, 12.73.

4-Amino-3- (3,5-dimethoxy phenyl) -5 - mercapto-1,2,4-triazole.(3b)

Yield: 62%; m.p: 200 °C; IR (KBr) ν (cm⁻¹) : 3286 (NH stretching), 1610 (C=N stretching); 3090 (aromatic CH stretching), 2580 (SH), 2934, 2847 (methyl CH stretch), 1264 (asymmetric C-O-C stretching), 1018 (symmetric C-O-C stretching), 1280 (N-N=C), 1588, 1548, 1486, 1455 (C=C ring stretching); ¹H NMR δ (ppm): 13.90 (s, 1H, SH), 7.2 (d, 2H, C-2 & C-6 of Ar), 6.7 (d, 1H, C-4 of Ar), 5.84 (s, 2H, NH₂), 3.84 (s, 6H, OCH₃); MS m/z : 252 M⁺; Anal. Calcd. (%) for C₁₀H₁₂N₄O₂S: C, 47.61; H, 4.79; N, 22.21; S, 12.71. Found: C, 47.50; H, 4.84; N, 22.26; S, 12.68.

4-Amino-3- (3,4,5-trimethoxy phenyl) -5 - mercapto -1,2,4-triazole. (3c)

Yield: 60%; m.p: 206 °C; IR (KBr) ν (cm⁻¹): 3271 (NH stretching), 1607 (C=N stretching), 3092 (aromatic CH stretching), 1571, 1558, 1480, 1451 (C=C ring stretching), 2585 (SH), 2935, 2838 (methyl CH stretch), 1261 (asymmetric C-O-C stretching), 1037 (symmetric C-O-C stretching), 1287 (N-N=C); ¹H NMR δ (ppm): 13.90 (s, 1H, SH), 7.36 (s, 2H, C-2 & C-6 of Ar), 5.82 (s, 2H, NH₂), 3.76 (s, 9H, OCH₃); MS m/z : 282 M⁺; Anal. Calcd. (%) for C₁₁H₁₄N₄O₃S: C, 46.80; H, 5.00; N, 19.85; S, 11.36. Found: C, 46.73; H, 4.97; N, 19.91; S, 11.33.

4-Amino-3- (4-pyridinyl) -5 - mercapto -1,2,4-triazole. (3d)

Yield: 65%; m.p: 262 °C; IR (KBr) ν (cm⁻¹): 3271 (NH stretching), 1607 (C=N stretching), 3080 (aromatic CH stretching), 1571, 1558, 1480, 1451 (C=C ring stretching), 2585 (SH), 2935, 2838 (methyl CH stretch), 1261 (asymmetric C-O-C stretching), 1037 (symmetric C-O-C stretching), 1287 (N-N=C); ¹H NMR δ (ppm): 14.10 (s, 1H, SH), 8.0 (d, 2H, C-3 & C-5 of Ar), 8.72 (d, 2H, C-2 & C-6 of Ar), 5.84 (s, 2H, NH₂); MS m/z : 193 M⁺; Anal. Calcd. (%) for C₇H₇N₅S: C, 43.51; H, 3.65; N, 36.24; S, 16.59. Found: C, 43.42; H, 3.68; N, 36.17; S, 16.57.

General method for the synthesis of 3-aryl/heteroaryl- 6- (2-substituted-4-quinolinyl)-1,2,4-triazolo [3,4-b]-1,3,4- thiadiazoles. 4(a-d)

A mixture of respective triazole (0.02mol), 2-phenyl-quinoline-4-carboxylic acid (0.02mol), and phosphorous oxychloride (10mL) was heated under reflux for 4-6 h. The reaction mixture was cooled to room temperature and the mixture was gradually poured onto crushed ice with stirring. Finely powdered potassium carbonate and the required amount of solid potassium hydroxide were added till the pH of the mixture was raised to 8, to remove the excess of phosphorous oxychloride. Allowed the mixture to stand overnight, solid was separated. It was filtered, washed thoroughly with cold water, dried and recrystallized from hot ethanol. Similarly other compounds were prepared.

3-(3,4-dimethoxyphenyl)-6-(2-phenyl-4-quinolinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (4a)

Yield: 52%, m.p: 222-224 °C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1604 (C=N stretching), 1591, 1572, 1490, 1451 (C=C ring stretch), 2940, 2840 (methyl CH stretch), 1264 (asymmetric C-O-C stretching), 1014 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.14-8.2 (m, Ar-H), 3.80 (s, 6H, OCH₃); MS *m/z*: 465 M⁺; Anal. Calcd. (%) for C₂₆ H₁₉ N₅ O₂ S: C, 67.08; H, 4.11; N, 15.04; S, 6.89. Found: C, 67.19; H, 4.14; N, 15.10; S, 6.86.

3-(3,5-dimethoxyphenyl)-6-(2-phenyl-4-quinolinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (4b)

Yield: 48%, m.p: 232 °C; IR (KBr) ν (cm⁻¹): 1611 (C=N stretching), 3085 (aromatic CH stretching), 1585, 1570, 1480 (C=C ring stretching), 2945, 2840 (methyl CH stretch), 1261 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 6.7-8.2 (m, Ar-H), 3.82 (s, 6H, OCH₃); MS *m/z*: 465 M⁺; Anal. Calcd. (%) for C₂₆ H₁₉ N₅ O₂ S: C, 67.08; H, 4.11; N, 15.04; S, 6.89. Found: C, 66.94; H, 4.08; N, 15.09; S, 6.85.

3-(3, 4, 5-trimethoxy phenyl)-6- (2-phenyl-4-quinolinyl)-1,2,4-triazolo[3,4-b] - 1,3,4-thiadiazole (4c)

Yield: 46%, m.p: 186 °C; IR (KBr) ν (cm⁻¹): 3095 (aromatic CH stretching), 1614 (C=N stretching), 1585, 1551, 1479, 1453 (C=C ring stretch), 1254 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching), 2955, 2840 (methyl CH stretch), 1274 (N-N=C); ¹H NMR δ (ppm): 7.3-8.2 (m, 12H, Ar-H), 3.86 (s, 9H, OCH₃); MS *m/z*: 495 M⁺; Anal. Calcd. (%) for C₂₇ H₂₁ N₅ O₃ S: C, 65.44; H, 4.27; N, 14.13; S, 6.47. Found: C, 65.57; H, 4.24; N, 14.07; S, 6.43.

3-(4-pyridinyl)-6- (2-phenyl-4-quinolinyl)-1,2,4-triazolo [3,4-b] -1,3,4-thiadiazole (4d)

Yield: 54%, m.p: 212°C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 7.4-8.2 (m, 13H, Ar-H), 8.70 (d, 2H, C-3 & C-5 of Ar); MS *m/z*: 406 M⁺; Anal. Calcd. (%) for C₂₃ H₁₄ N₆ S: C, 67.96; H, 3.47; N, 20.68; S, 7.89. Found: C, 68.07; H, 3.45; N, 20.79; S, 7.85.

3-(3,4-dimethoxyphenyl)-6-(2-methyl-4-quinolinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (5a)

Yield: 56%; m.p: 170°C; IR (KBr) ν (cm⁻¹): 3085 (aromatic CH stretching), 1610 (C=N stretching), 1594, 1480, 1450 (C=C ring stretch), 2960, 2840 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching), 1286 (N-N=C); ¹H NMR δ : 7.20-8.0 (m, Ar-H), 3.80 (s, 3H, OCH₃), 2.78 (s, 3H, CH₃); MS *m/z*: 404 M⁺; Anal. Calcd. (%) for C₂₁H₁₇N₅O₂S: C, 62.52; H, 4.25; N, 17.36; S, 7.95. Found: C, 62.61; H, 4.25; N, 17.39; S, 7.92.

3-(3,5-dimethoxyphenyl)-6-(2-methyl-4-quinolinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (5b)

Yield: 52%; m.p: 186°C; IR (KBr) ν (cm⁻¹): 1608 (C=N stretching), 3080 (aromatic CH stretching), 1580, 1560, 1480 (C=C ring stretching), 2942, 2846 (methyl CH stretch), 1266 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 6.72-8.02 (m, Ar-H), 3.84 (s, 6H, OCH₃), 2.80 (s, 3H, CH₃); MS *m/z*: 403 M⁺; Anal. Calcd. (%) for C₂₁H₁₇N₅O₂S: C, 62.52; H, 4.25; N, 17.36; S, 7.95. Found: C, 62.44; H, 4.21; N, 17.32; S, 7.98.

3-(3, 4, 5-trimethoxy phenyl)-6- (2-methyl-4-quinolinyl)-1,2,4-triazolo [3,4-b] - 1,3,4-thiadiazole (5c)

Yield: 53%; m.p: 178°C; IR (KBr) ν (cm⁻¹): 3090 (aromatic CH stretching), 1610 (C=N stretching), 1580, 1561, 1484 (C=C ring stretch), 2965, 2848 (methyl CH stretch), 1262 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching), 1276 (N-N=C); ¹H NMR δ (ppm): 7.30-8.02 (m, Ar-H), 3.86 (s, 9H, OCH₃), 2.82 (s, 3H, CH₃ of Ar'); MS *m/z*: 433 M⁺; Anal. Calcd. (%) for C₂₂H₁₉N₅O₃S: C, 60.96; H, 4.42; N, 16.16; S, 7.40. Found: C, 61.09; H, 4.39; N, 16.21; S, 7.38.

3-(4-pyridinyl)-6- (2-methyl-4-quinolinyl)-1,2,4-triazolo [3,4-b] -1,3,4-thiadiazole (5d)

Yield: 45%; m.p: 206°C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ : 7.32-8.1 (m, 5H of Ar'), 8.42 (d, 2H, C-3 & C-5 of Ar'); 8.80 (d, 2H, C-2 & C-6 of Ar'); 2.8 (s, 3H, CH₃); MS *m/z*: 344 M⁺; Anal. Calcd. (%) for C₁₈H₁₂N₆S: C, 62.77; H, 3.51; N, 24.40; S, 9.31. Found: C, 62.85; H, 3.49; N, 24.47; S, 9.28.

3-(3,4-dimethoxy phenyl)-6-(4-quinolinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (6a)

Yield: 46%; m.p: 240 °C; IR (KBr) ν (cm⁻¹): 3073 (aromatic CH stretching), 1607 (C=N stretching), 1592, 1570 (C=C ring stretch), 2945, 2854 (methyl CH stretch), 1267 (asymmetric C-O-C stretching), 1023 (symmetric C-O-C stretching), 1275 (N-N=C); ¹H NMR δ (ppm): 7.18-7.7 (m, Ar-H), 8.05 (d, 1H, C-8' of Ar'), 8.88 (d, 1H, C-2' of Ar'), 3.80 (s, 6H, OCH₃); MS *m/z*: 389 M⁺; Anal. Calcd. (%) for C₂₀H₁₅N₅O₂S: C, 61.68; H, 3.88; N, 17.98; S, 8.23. Found: C, 61.56; H, 3.91; N, 18.05; S, 8.19.

3-(3,5-dimethoxy phenyl)-6-(4-quinolinyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (6b)

Yield: 49%; m. p: 248°C; IR (KBr) ν (cm⁻¹): 3065 (aromatic CH stretching), 1586, 1566 (C=C ring stretching), 2960, 2854 (methyl CH stretch), 1616 (C=N stretching), 1258 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching), 1281 (N-N=C); ¹H NMR δ (ppm): 6.70-7.7 (m, Ar-H), 8.05 (d, 1H, C-8' of Ar'), 8.9 (d, 1H, C-2' of Ar'), 3.84 (s, 6H, OCH₃); MS *m/z*: 389 M⁺; Anal. Calcd. (%) for C₂₀H₁₅N₅O₂S: C, 61.68; H, 3.88; N, 17.98; S, 8.23. Found: C, 61.79; H, 3.85; N, 18.05; S, 8.20.

3-(3, 4, 5-trimethoxy phenyl)-6-(4-quinoliny)-1,2,4-triazolo [3,4-b] -1,3,4-thiadiazole (6c)

Yield: 47%; m.p: 234°C; IR (KBr) ν (cm⁻¹): 3078 (aromatic CH stretching), 1614 (C=N stretching), 1590, 1575 (C=C ring stretch), 2970, 2848 (methyl CH stretch), 1263 (asymmetric C-O-C stretching), 1018 (symmetric C-O-C stretching), 1284 (N-N=C); ¹H NMR δ (ppm): 7.30-7.74 (m, Ar-H), 8.05 (d, 1H, C-8' of Ar'), 8.9 (d, 1H, C-2' of Ar'), 3.86 (s, 9H, OCH₃); MS m/z : 419 M⁺; Anal. Calcd. (%) for C₂₁H₁₇N₅O₃ S: C, 60.13; H, 4.09; N, 16.70; S, 7.64. Found: C, 60.01; H, 4.12; N, 16.65; S, 7.61.

3-(4-pyridinyl)-6-(4-quinoliny)-1,2,4-triazolo[3,4-b] -1,3,4-thiadiazole (6d)

Yield: 54%; m.p: 284°C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ : 7.4-7.7 (m, 4H, of Ar'), 7.96 (d, 2H, C-2 & C-6 of Ar), 8.7 (d, 2H, C-2 & C-6 of Ar), 8.05 (d, 1H, C-8' of Ar'), 8.9 (d, 1H, C-2' of Ar'); MS m/z : 330 M⁺; Anal. Calcd. (%) for C₁₇H₁₀N₆S: C, 61.80; H, 3.05; N, 25.44; S, 9.71. Found: C, 61.73; H, 3.07; N, 25.40; S, 9.68.

3-(3, 4-dimethoxy phenyl)-6-(2, 6-dihydroxy-4-pyridinyl)-1, 2, 4-triazolo [3,4-b]-1, 3, 4-thiadiazole (7a)

Yield: 50%; m.p: 280°C(dec.); IR (KBr) ν (cm⁻¹): 3430 (OH stretching), 3074 (aromatic CH stretching), 1612 (C=N stretching), 1590, 1541, 1480, 1455 (C=C ring stretch), 2965, 2931 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1026 (symmetric C-O-C stretching), 1290 (N-N=C); ¹H NMR δ (ppm): 7.12 (d, 1H, C-5 of Ar), 7.52 (s, 1H, C-2 of Ar), 7.66 (d, 1H, C-6 of Ar), 7.26 (s, 2H, C-3 & C-5 of Ar'), 6.14 (s, 2H, OH), 3.8 (s, 6H, OCH₃); MS m/z : 371 M⁺; Anal. Calcd. (%) for C₁₆H₁₃N₅O₄ S: C, 51.75; H, 3.53; N, 18.86; S, 8.63. Found: C, 51.64; H, 3.56; N, 18.81; S, 8.59.

3-(3, 5-dimethoxy phenyl)-6-(2,6-dihydroxy-4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (7b)

Yield: 52%; m.p: 294 °C (dec.); IR (KBr) ν (cm⁻¹): 3443 (OH stretching), 3076, 3034 (aromatic CH stretching), 1607(C=N stretching), 1590, 1538, 1478, 1448 (C=C ring stretch), 2970, 2934 (methyl CH stretch), 1262 (asymmetric C-O-C stretching), 1015 (symmetric C-O-C stretching), 1283 (N-N=C); ¹H NMR δ (ppm): 6.74 (d, 1H, C-4 of Ar), 7.20 (d, 2H, C-2 & C-6 of Ar), 7.28 (s, 2H, C-3 & C-5 of Ar'), 6.20 (s, 2H, OH), 3.84 (s, 6H, OCH₃); MS m/z : 371 M⁺; Anal. Calcd. (%) for C₁₆H₁₃N₅O₄ S: C, 51.75; H, 3.53; N, 18.86; S, 8.63. Found: C, 51.67; H, 3.53; N, 18.91; S, 8.62.

3-(3, 4, 5-trimethoxy phenyl)-6-(2, 6-dihydroxy-4-pyridinyl)-1, 2, 4-triazolo[3,4-b]-1, 3,4-thiadiazole (7c)

Yield: 50%; m.p: 282 °C (dec.); IR (KBr) ν (cm⁻¹): 3450 (OH stretching), 3080 (aromatic CH stretching), 1610 (C=N stretching), 1590, 1564, 1482, 1448 (C=C ring stretch), 2958, 2930 (methyl CH stretch), 1264 (asymmetric C-O-C stretching), 1023 (symmetric C-O-C stretching), 1286 (N-N=C); ¹H NMR δ (ppm): 7.36 (s, 2H, C-2 & C-6 of Ar), 7.24 (s, 2H, C-3 & C-5 of Ar'), 3.88 (s, 9H, OCH₃), 6.20 (s, 2H, OH); MS m/z : 401 M⁺; Calcd. (%) for C₁₇H₁₅N₅O₅ S: C, 50.87; H, 3.77; N, 17.45; S, 7.99. Found: C, 50.81; H, 3.74; N, 17.51; S, 7.95.

3-(4-pyridinyl)-6-(2, 6-dihydroxy-4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (7d)

Yield: 48%; m.p: 300 °C (dec.); IR (KBr) ν (cm⁻¹): 3442 (OH stretching), 3087, (aromatic CH stretching), 1612 (C=N stretching), 1585, 1558 (C=C ring stretch), 1283 (N-N=C); ¹H NMR δ (ppm): 8.00 (d, 2H, C-3 & C-5 of Ar), 8.72 (d, 2H, C-2 & C-6 of Ar), 7.24 (s, 2H, C-3' & C-5' of Ar'), 6.20 (s, 2H, OH); MS *m/z*: 312 M⁺; Anal. Calcd. (%) for C₁₃H₈N₆O₂S: C, 50.00; H, 2.58; N, 26.91; S, 10.27. Found: C, 49.91; H, 2.60; N, 26.83; S, 10.25.

3-(3, 4-dimethoxy phenyl)-6-(2-chloro-4-pyridinyl)-1, 2, 4-triazolo [3,4-b]-1, 3, 4-thiadiazole (8a)

Yield: 50 %; m.p: 218°C; IR (KBr) ν (cm⁻¹): 3065 (aromatic CH stretching), 1610 (C=N stretching), 1585, 1567, 1484, 1455 (C=C ring stretch), 2970, 2840 (methyl CH stretch), 1254 (asymmetric C-O-C stretching), 1034(symmetric C-O-C stretching), 1275 (N-N=C); ¹H NMR δ (ppm): 7.16 (d, 1H, C-5 of Ar), 7.54 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 8.00 (s, 1H, C-3' of Ar'), 7.9 (d, 1H, C-5' of Ar'), 8.9 (d, 1H, C-6' of Ar'), 3.82 (s, 6H, OCH₃); MS *m/z*: 373 M⁺, 375 M⁺²; Anal. Calcd. (%) for C₁₆H₁₂N₅O₂S Cl: C, 51.41; H, 3.24; N, 18.73; S, 8.58. Found: C, 51.52; H, 3.27; N, 18.64; S, 8.54.

3-(3,5-dimethoxy phenyl)-6-(2-chloro-4-pyridinyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (8b)

Yield: 47%; m.p: 224 °C; IR (KBr) ν (cm⁻¹): 3084, 3048 (aromatic CH stretching), 1607 (C=N stretching), 1585, 1554, 1464, 1448 (C=C ring stretch), 2984, 2854 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1028 (symmetric C-O-C stretching), 1284 (N-N=C); ¹H NMR δ (ppm): 7.26 (d, 2H, C-2 & C-6 of Ar), 6.74 (d, 1H, C-4 of Ar), 8.00 (s, 1H, C-3' of Ar'), 7.9 (d, 1H, C-5' of Ar'), 8.88 (d, 1H, C-6' of Ar'), 3.86 (s, 6H, OCH₃); MS *m/z*: 373 M⁺, 375 M⁺²; Anal. Calcd. (%) for C₁₆H₁₂N₅O₂S Cl: C, 51.41; H, 3.24; N, 18.73; S, 8.58. Found: C, 51.37; H, 3.24; N, 18.69; S, 8.56.

3-(3, 4, 5-trimethoxy phenyl)-6-(2-chloro-4-pyridinyl)-1, 2, 4-triazolo[3,4-b]-1, 3,4-thiadiazole (8c)

Yield: 48 %; m.p: 226°C(dec.); IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1614 (C=N stretching), 1587, 1550, 1482 (C=C ring stretch), 1264 (asymmetric C-O-C stretching), 1017 (symmetric C-O-C stretching), 2958, 2854 (methyl CH stretch), 1276 (N-N=C); ¹H NMR δ (ppm): 7.34 (s, 2H, C-2 & C-6 of Ar), 8.00 (s, 1H, C-3' of Ar'), 7.9 (d, 1H, C-5' of Ar'), 8.90 (d, 1H, C-6' of Ar'), 3.86 (s, 9H, OCH₃); MS *m/z*: 403 M⁺, 405 M⁺²; Anal. Calcd. (%) for C₁₇H₁₄N₅O₃S Cl: C, 50.56; H, 3.49; N, 17.34; S, 7.94. Found: C, 50.47; H, 3.50; N, 17.29; S, 7.91.

3-(4-pyridinyl)-6-(2-chloro-4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (8d)

Yield: 48 %; m.p: 270°C(dec.); IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 8.00 (d, 2H, C-3 & C-5 of Ar), 8.7 (d, 2H, C-2 & C-6 of Ar), 8.02 (s, 1H, C-3' of Ar'), 7.9 (d, 1H, C-5' of Ar'), 8.90 (d, 1H, C-6' of Ar'); MS *m/z*: 314 M⁺, 316 M⁺²; Anal. Calcd. (%) for C₁₃H₇N₆S Cl: C, 49.61; H, 2.24; N, 26.70; S, 10.19. Found: C, 49.52; H, 2.26; N, 26.75; S, 10.14.

3-(3, 4-dimethoxy phenyl)-6-(2-flouro-4-pyridinyl)-1, 2, 4-triazolo [3,4-b]-1, 3, 4-thiadiazole (9a)

Yield: 49 %; m.p: 206°C(dec.); IR (KBr) ν (cm⁻¹): 3082 (aromatic CH stretching), 1618 (C=N stretching), 1580, 1564 (C=C ring stretch), 2964, 2846 (methyl CH stretch), 1258 (asymmetric C-O-C stretching), 1028(symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.12 (d, 1H, C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.76 (d, 1H, C-6 of Ar), 7.7 (s, 1H, C-3' of Ar'), 7.9 (d, 1H, C-5' of Ar'), 8.60 (d, 1H, C-6' of Ar'), 3.86 (s, 6H, OCH₃); MS *m/z*: 357 M⁺; Anal. Calcd. (%) for C₁₆ H₁₂ N₅ O₂ S F: C, 53.77; H, 3.38; N, 19.60; S, 8.97. Found: C, 53.68; H, 3.41; N, 19.64; S, 8.93.

3-(3,5-dimethoxyphenyl)-6-(2-flouro-4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole(9b)

Yield: 46 %; m.p: 190°C(dec); IR (KBr) ν (cm⁻¹): 3090 (aromatic CH stretching), 1617 (C=N stretching), 1575, 1560 (C=C ring stretch), 2954, 2837 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching), 1284 (N-N=C); ¹H NMR δ (ppm): 7.24 (d, 2H, C-2 & C-6 of Ar), 6.72 (d, 1H, C-4 of Ar), 7.68 (s, 1H, C-3' of Ar'), 7.90(d, 1H, C-5' of Ar'), 8.60 (d, 1H, C-6' of Ar'), 3.80 (s, 6H, OCH₃); MS *m/z*: 357 M⁺; Anal. Calcd. (%) for C₁₆ H₁₂ N₅ O₂ S F: C, 53.77; H, 3.38; N, 19.60; S, 8.97. Found: C, 53.83; H, 3.36; N, 19.55; S, 8.95.

3-(3, 4, 5-trimethoxy phenyl)-6-(2-flouro-4-pyridinyl)-1, 2, 4-triazolo[3,4-b]-1, 3, 4-thiadiazole (9c)

Yield: 53 %; m.p: 210°C (dec); IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1614 (C=N stretching), 1587, 1550, 1482 (C=C ring stretch), 1267 (asymmetric C-O-C stretching), 1019 (symmetric C-O-C stretching), 2958, 2854 (methyl CH stretch), 1276 (N-N=C); ¹H NMR δ (ppm): ¹H NMR δ (ppm): 7.32 (s, 2H of Ar), 7.68 (s, 1H, C-3' of Ar'), 7.88 (d, 1H, C-5' of Ar'), 8.58 (d, 1H, C-6' of Ar'), 3.86 (s, 9H, OCH₃); MS *m/z*: 387 M⁺; Anal. Calcd. (%) for C₁₇ H₁₄ N₅ O₃ S F: C, 52.71; H, 3.64; N, 18.08; S, 8.28. Found: C, 52.65; H, 3.64; N, 18.15; S, 8.32.

3-(4-pyridinyl)-6-(2-flouro-4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (9d)

Yield: 51 %; m.p: 206°C(dec); IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 8.0 (d, 2H, C-3 & C-5 of Ar), 8.8 (d, 2H, C-2 & C-6 of Ar), 7.68 (s, 1H, C-3' of Ar'), 7.88 (d, 1H, C-5' of Ar'), 8.62 (d, 1H, C-6' of Ar'); MS *m/z*: 298 M⁺; Anal. Calcd. (%) for C₁₃ H₇ N₆ S F: C, 52.34; H, 2.37; N, 28.17; S, 10.75. Found: C, 52.25; H, 2.39; N, 28.24; S, 10.71.

3-(3, 4-dimethoxy phenyl)-6-(5-methoxy-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (10a)

Yield: 48 %; m.p: 160°C; IR (KBr) ν (cm⁻¹): 3084 (aromatic CH stretching), 1614 (C=N stretching), 1587, 1565 (C=C ring stretch), 2980, 2849 (methyl CH stretch), 1265 (asymmetric C-O-C stretching), 1018 (symmetric C-O-C stretching), 1282 (N-N=C); ¹H NMR δ (ppm): 7.16 (d,1H of Ar), 7.52 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 7.4 (m, 2H, C-4' & C-6' of Ar'), 7.78 (d, 1H, C-7' of Ar'), 6.86 (s, 1H, C-2' of Ar'), 3.82 (s, 6H, OCH₃ in Ar), 3.74 (s, 3H, OCH₃ in Ar'), 4.10 (s, 2H, CH₂), 10.10 (s, 1H, NH of Ar); MS *m/z*: 421 M⁺; Anal. Calcd. (%) for C₂₁ H₁₉ N₅ O₃ S: C, 59.84; H, 4.54; N, 16.62; S, 7.61. Found: C, 59.75; H, 4.54; N, 16.67; S, 7.58.

3-(3, 5-dimethoxy phenyl)-6-(5-methoxy-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (10b)

Yield: 50 %; m.p: 176° C; IR (KBr) ν (cm⁻¹): 3070 (aromatic CH stretching), 1624 (C=N stretching), 1588, 1546 (C=C ring stretch), 2956, 2864 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 1285 (N-N=C); ¹H NMR δ (ppm): 7.20 (d, 2H, C-2 & C-6 of Ar), 6.76 (d, 1H, C-4 of Ar), 7.40 (m, 2H, C-4' & C-6' of Ar'), 7.80 (d, 1H, C-7' of Ar'), 6.84 (s, 1H, C-2' of Ar'), 4.10 (s, 2H, CH₂ of methylene), 3.84 (s, 6H, OCH₃ in Ar), 3.76 (s, 3H, OCH₃ in Ar'), 10.10 (s, 1H, NH of Ar'); MS *m/z*: 421 M⁺; Anal. Calcd. (%) for C₂₁H₁₉N₅O₃S: C, 59.84; H, 4.54; N, 16.62; S, 7.61. Found: C, 59.72; H, 4.56; N, 16.56; S, 7.64.

3-(3, 4, 5-trimethoxy phenyl)-6-(5-methoxy-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (10c)

Yield: 54 %; m.p: 168°C; IR (KBr) ν (cm⁻¹): 3063 (aromatic CH stretching), 1616 (C=N stretching), 1587, 1549, 1479, 1452 (C=C ring stretch), 2964, 2838 (methyl CH stretch), 1267 (asymmetric C-O-C stretching), 1029 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.32 (s, 2H, C-2 & C-6 of Ar), 7.46 (m, 2H, C-4' & C-6' of Ar'), 7.78 (d, 1H, C-7' of Ar'), 6.80 (s, 1H, C-2' of Ar'), 4.10 (s, 2H, CH₂ of methylene), 3.86 (s, 9H, OCH₃ in Ar), 3.76 (s, 3H, OCH₃ in Ar'), 10.10 (s, 1H, NH of Ar'); MS *m/z*: 451 M⁺; Anal. Calcd. (%) for C₂₂H₂₁N₅O₄S: C, 58.52; H, 4.69; N, 15.51; S, 7.10. Found: C, 58.41; H, 4.71; N, 15.46; S, 7.06.

3-(4-pyridinyl)-6-(5-methoxy-3-indolylmethyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole(10d)

Yield: 46 %; m.p: 224°C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 8.0 (d, 2H, C-3 & C-5 of Ar), 8.72 (d, 2H, C-2 & C-6 of Ar), 7.42 (m, 2H, C-4' & C-6' of Ar'), 7.78 (d, 1H, C-7' of Ar'), 6.80 (s, 1H, C-2 of pyrrole), 4.12 (s, 2H, CH₂ of methylene), 3.76 (s, 3H, OCH₃), 10.08 (s, 1H, NH of Ar'); MS *m/z*: 362 M⁺; Anal. Calcd. (%) for C₁₈H₁₄N₆O S: C, 59.66; H, 3.89; N, 23.19; S, 8.85. Found: C, 59.54; H, 3.90; N, 23.16; S, 8.81.

3-(3, 4-dimethoxy phenyl)-6-(5-methoxy-2-methyl-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (11a)

Yield: 50 %; m.p: 190°C; IR (KBr) ν (cm⁻¹): 3075 (aromatic CH stretching), 1610 (C=N stretching), 1587, 1565 (C=C ring stretch), 2980, 2849 (methyl CH stretch), 1265 (asymmetric C-O-C stretching), 1018 (symmetric C-O-C stretching), 1282 (N-N=C); ¹H NMR δ (ppm): 7.18 (d, 1H, C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.72 (d, 1H, C-6 of Ar), 7.44 (d, 1H, C-7' of Ar'), 7.00 (s, 1H, C-4' of Ar'), 7.32 (d, 1H, C-6' of Ar'), 3.80 (s, 3H, OCH₃ of Ar), 3.76 (s, 6H, OCH₃ of Ar'), 4.10 (s, 2H, CH₂), 10.10 (s, 1H, NH of Ar'), 2.84 (s, 3H, CH₃); MS *m/z*: 435 M⁺; Anal. Calcd. (%) for C₂₂H₂₁N₅O₃S: C, 60.67; H, 4.86; N, 16.08; S, 7.36. Found: C, 60.79; H, 4.83; N, 16.14; S, 7.31.

3-(3, 5-dimethoxy phenyl)-6-(5-methoxy-2-methyl-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (11b)

Yield: 47 %; m.p: 182°C; IR (KBr) ν (cm⁻¹): 3082 (aromatic CH stretching), 1610 (C=N stretching), 1588, 1561 (C=C ring stretch), 2956, 2856 (methyl CH stretch), 1268 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching), 1286 (N-N=C); ¹H NMR δ (ppm): 7.20 (d, 2H, C-2 & C-6 of Ar), 6.74 (d, 1H, C-4 of Ar), 7.48 (d, 1H, C-7' of Ar'), 7.00 (s, 1H, C-4' of Ar'), 7.34 (d, 1H, C-6' of Ar'), 4.10 (s, 2H, CH₂ of methylene), 3.82 (s, 6H, OCH₃ in Ar), 3.76 (s, 3H, OCH₃ in Ar'), 10.10 (s, 1H, NH of Ar'), 2.84 (s, 3H, CH₃); MS *m/z*: 435 M⁺; Anal. Calcd. (%) for C₂₂H₂₁N₅O₃S: C, 60.67; H, 4.86; N, 16.08; S, 7.36. Found: C, 60.72; H, 4.84; N, 16.12; S, 7.33.

3-(3, 4, 5-trimethoxy phenyl)-6-(5-methoxy-2-methyl-3-indolyl methyl)-1,2,4-triazolo [3,4-b] -1,3,4-thiadiazole (11c)

Yield: 50 %; m.p: 186°C; IR (KBr) ν (cm⁻¹): 3068 (aromatic CH stretching), 1616 (C=N stretching), 1587, 1554 (C=C ring stretch), 2943, 2860 (methyl CH stretch), 1258 (asymmetric C-O-C stretching), 1023 (symmetric C-O-C stretching), 1288 (N-N=C); ¹H NMR δ (ppm): 7.20 (s, 2H C-2 & C-6 of Ar), 7.58 (d, 1H, C-7' of Ar'), 6.96 (s, 1H, C-4' of Ar'), 7.36 (d, 1H, C-6' of Ar'), 4.24 (s, 2H, CH₂ of methylene), 3.8 (s, 9H, OCH₃ in Ar), 3.76 (s, 3H, OCH₃ in Ar'), 10.08 (s, 1H, NH of Ar'), 2.84 (s, 3H, CH₃); MS *m/z*: 465 M⁺; Anal. Calcd. (%) for C₂₃H₂₃N₅O₄S: C, 59.34; H, 4.98; N, 15.04; S, 6.89. Found: C, 59.46; H, 4.97; N, 15.09; S, 6.85.

3-(4-pyridinyl)-6-(5-methoxy-2-methyl-3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (11d)

Yield: 53 %; m.p: 240°C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 8.0 (d, 2H, C-3 & C-5 of Ar), 8.72 (d, 2H, C-2 & C-6 of Ar), 7.00 (s, 1H, C-4' of Ar'), 7.28 (d, 1H, C-6' of Ar'), 7.56 (d, 1H, C-7' of Ar'), 4.10 (s, 2H, CH₂ of methylene), 3.76 (s, 3H, OCH₃ in Ar'), 10.06 (s, 1H, NH of Ar'), 2.84 (s, 3H, CH₃); MS *m/z*: 376 M⁺; Anal. Calcd. (%) for C₁₉H₁₆N₆O S: C, 60.62; H, 4.28; N, 22.33; S, 8.52. Found: C, 60.56; H, 4.30; N, 22.27; S, 8.49.

3-(3, 4-dimethoxy phenyl)-6-(3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (12a)

Yield: 58 %; m.p: 184°C; IR (KBr) ν (cm⁻¹): 3092 (aromatic CH stretching), 1623 (C=N stretching), 1583, 1545 (C=C ring stretch), 2980, 2855 (methyl CH stretch), 1267 (asymmetric C-O-C stretching), 1018 (symmetric C-O-C stretching), 1282 (N-N=C); ¹H NMR δ (ppm): 7.1 (d, 1H C-5 of Ar), 7.54 (s, 1H, C-2 of Ar), 7.70 (d, 1H, C-6 of Ar), 7.20 (s, 4H, C-4, C-5, C-6 & C-7 of Ar'), 6.8 (s, 1H of C-2 of Ar'), 3.80 (s, 6H, OCH₃ in Ar), 4.20 (s, 2H, CH₂), 10.08 (s, 1H, NH of Ar'); MS *m/z*: 391 M⁺; Anal. Calcd. (%) for C₂₀H₁₇N₅O₂S: C, 61.37; H, 4.38; N, 17.89; S, 8.19. Found: C, 61.26; H, 4.41; N, 17.82; S, 8.15.

3-(3, 5-dimethoxy phenyl)-6-(3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (12b)

Yield: 58 %; m.p: 174°C; IR (KBr) ν (cm⁻¹): 3071 (aromatic CH stretching), 1608 (C=N stretching), 1574, 1540 (C=C ring stretch), 2956, 2834 (methyl CH stretch), 1261 (asymmetric C-O-C stretching), 1019 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.28 (d, 2H, C-2 & C-6 of Ar), 6.64 (d, 1H, C-4 of Ar), 7.20 (s, 4H, C-4, C-5, C-6 & C-7 of Ar'), 6.8 (s, 1H of C-2 of Ar'), 4.10 (s, 2H, CH₂), 10.08 (s, 1H, NH of Ar'), 3.84 (s, 6H, OCH₃ in Ar); MS *m/z*: 391 M⁺; Anal. Calcd. (%) for C₂₀H₁₇N₅O₂S: C, 61.37; H, 4.38; N, 17.89; S, 8.19. Found: C, 61.33; H, 4.38; N, 17.86; S, 8.16.

3-(3, 4, 5-trimethoxy phenyl)-6-(3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (12c)

Yield: 50 %; m.p: 180°C; IR (KBr) ν (cm⁻¹): 3060 (aromatic CH stretching), 1616 (C=N stretching), 1571, 1549 (C=C ring stretch), 2952, 2839 (methyl CH stretch), 1259 (asymmetric C-O-C stretching), 1022 (symmetric C-O-C stretching), 1271 (N-N=C); ¹H NMR δ (ppm): 7.36 (s, 2H, C-2 & C-6 of Ar), 7.20 (s, 4H, C-4, C-5, C-6 & C-7 of Ar'), 6.8 (s, 1H of C-2 of Ar'), 4.10 (s, 2H, CH₂), 10.08 (s, 1H, NH of Ar'), 3.86 (s, 9H, OCH₃ of Ar); MS *m/z*: 421 M⁺; Anal. Calcd. (%) for C₂₁H₁₉N₅O₃S: C, 59.84; H, 4.54; N, 16.62; S, 7.61. Found: C, 59.73; H, 4.57; N, 16.65; S, 7.58.

3-(4-pyridinyl)-6-(3-indolyl methyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (12d)

Yield: 55 %; m.p: 232 °C; IR (KBr) ν (cm⁻¹): 3080 (aromatic CH stretching), 1611 (C=N stretching), 1580, 1560 (C=C ring stretch), 1286 (N-N=C); ¹H NMR δ (ppm): 8.0 (d, 1H, C-3 & C-5 of Ar), 8.7 (d, 1H, C-2 & C-6 of Ar), 7.20 (s, 4H, C-4, C-5, C-6 & C-7 of Ar'), 6.8 (s, 1H of C-2 of Ar'), 4.10 (s, 2H, CH₂), 10.18 (s, 1H, NH of Ar'); MS *m/z*: 332 M⁺; Anal. Calcd. (%) for C₁₇H₁₂N₆S: C, 61.43; H, 3.64; N, 25.28; S, 9.65. Found: C, 61.34; H, 3.66; N, 25.22; S, 9.61.

3-(3,4-dimethoxy phenyl)-6-(4-hydroxy-3-methoxy cinnamyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (13a)

Yield: 62%; m.p: 194 °C; IR (KBr) ν (cm⁻¹): 3435 (OH stretching), 3036 (aromatic CH stretching), 1614 (C=N stretching), 1590, 1549, 1477, 1453 (C=C ring stretch), 2977, 2840 (methyl CH stretch), 1265 (asymmetric C-O-C stretching), 1023 (symmetric C-O-C stretching), 1280 (N-N=C), 1636 (vinyl group); ¹H NMR δ (ppm): 7.16 (d, 1H C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 7.76 (s, 1H, C-2 of Ar'), 7.42 (d, 1H, C-5 of Ar'), 7.8 (d, 1H, C-6 of Ar'), 3.74 (s, 3H, OCH₃ of Ar'), 3.84 (s, 6H, OCH₃ of Ar), 6.96 (d, 1H, CH), 6.8 (d, 1H, CH), 6.14 (s, 1H, OH); MS *m/z*: 410 M⁺; Anal. Calcd. (%) for C₂₀H₁₈N₄O₄S: C, 58.52; H, 4.42; N, 13.65; S, 7.81. Found: C, 58.43; H, 4.41; N, 13.68; S, 7.78.

3-(3,5-dimethoxy phenyl)-6-(4-hydroxy-3-methoxy cinnamyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (13b)

Yield: 62%; m.p: 188 °C; IR (KBr) ν (cm⁻¹): 3443 (OH stretching), 3040 (aromatic CH stretching), 1614 (C=N stretching), 1588, 1541, 1477, 1452 (C=C ring stretch), 2956, 2909 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1019 (symmetric C-O-C stretching), 1290 (N-N=C), 1636 (vinyl group); ¹H NMR δ (ppm): 7.24 (d, 2H, C-2 & C-6 of Ar), 6.64 (d, 1H, C-4 of Ar), 7.72 (s, 1H, C-2 of Ar'), 7.46 (d, 1H, C-4 of Ar'), 7.8 (d, 1H, C-6 of Ar'), 6.96 (d, 1H, CH), 6.8 (d, 1H, CH), 3.74 (s, 3H, OCH₃ of Ar'), 3.84 (s, 6H, OCH₃ of Ar), 6.14 (s, 1H, OH); MS *m/z*: 410 M⁺; Anal. Calcd. (%) for C₂₀H₁₈N₄O₄S: C, 58.52; H, 4.42; N, 13.65; S, 7.81. Found: C, 58.44; H, 4.43; N, 13.61; S, 7.84.

3-(3,4,5-trimethoxy phenyl)-6-(4-hydroxy-3-methoxy cinnamyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (13c)

Yield: 60%; m.p: 146-148 °C; IR (KBr) ν (cm⁻¹): 3437 (OH stretching), 3047 (aromatic CH stretching), 1616 (C=N stretching), 1587, 1549, 1479, 1452 (C=C ring stretch), 2927 (methyl CH stretch), 1263 (asymmetric C-O-C stretching), 1017 (symmetric C-O-C stretching), 1280 (N-N=C), 1640 (vinyl group); ¹H NMR δ (ppm): 7.30 (s, 2H, C-2 & C-6 of Ar), 7.74 (s, 1H, C-2 of Ar'), 7.46 (d, 1H, C-4 of Ar), 7.8 (d, 1H, C-6 of Ar), 7.0 (d, 1H, CH), 6.86 (d, 1H, CH), 3.74 (s, 3H, OCH₃ of Ar'), 3.88 (s, 9H, OCH₃ of Ar), 6.12 (s, 1H, OH); MS *m/z*: 440 M⁺; Anal. Calcd. (%) for C₂₁H₂₀N₄O₅S: C, 57.26; H, 4.58; N, 12.72; S, 7.28. Found: C, 57.35; H, 4.54; N, 12.67; S, 7.23.

3-(4-pyridinyl)-6-(4-hydroxy-3-methoxy cinnamyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (13d)

Yield: 64%; m.p: 210 °C; IR (KBr) ν (cm⁻¹): 3445 (OH stretching), 3069 (aromatic CH stretching), 1620 (C=N stretching), 1578, 1554 (C=C ring stretch), 2960, 2844 (methyl CH stretch), 1276 (N-N=C), 1636 (vinyl group); ¹H NMR δ (ppm): 8.0 (d, 1H, C-3 & C-5 of Ar), 8.7 (d, 1H, C-2 & C-6 of Ar), 7.74 (s, 1H, C-2 of Ar'), 7.46 (d, 1H, C-4 of Ar), 7.8 (d, 1H, C-6 of Ar), 7.00 (d, 1H, CH) 6.88, (d, 1H, CH), 6.14 (s, 1H, OH), 3.74 (3s, 3H, OCH₃ in Ar'); MS *m/z*: 351 M⁺; Anal. Calcd. (%) for C₁₇H₁₃N₅O₂S: C, 58.11; H, 3.73; N, 19.93; S, 9.13. Found: C, 57.97; H, 3.71; N, 19.97; S, 9.10.

3-(3,4-dimethoxy phenyl)-6-(2-amino-3,5-dibromo phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (14a)

Yield:46%; m.p: 242-246 °C;IR (KBr) ν (cm⁻¹): 3290 (NH stretching), 3190, 3060 (aromatic CH stretching), 1614 (C=N stretching), 1584, 1553, 1482, 1456 (C=C ring stretch), 2958, 2932 (methyl CH stretch), 1264 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.14 (d, 1H C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 7.88 (s, 1H, C-4 of Ar'), 7.96 (s, 1H, C-6 of Ar'), 6.28 (s, 2H, NH₂), 3.80 (s, 6H, OCH₃); MS *m/z*: 511 M⁺, 513 M⁺², 515 M⁺⁴; Anal. Calcd. (%) for C₁₇H₁₃N₅O₂S Br₂: C, 39.94; H, 2.56; N, 13.70; S, 6.27. Found: C, 39.84; H, 2.59; N, 13.65; S, 6.29.

3-(3,5-dimethoxy phenyl)-6-(2-amino-3, 5-dibromo phenyl)-1,2,4-triazolo [3,4-b] 1,3,4-thiadiazole (14b)

Yield: 48%; m.p: 228 °C; IR (KBr) ν (cm⁻¹): 3298 (NH stretching), 3140, 3074 (aromatic CH stretching), 1610 (C=N stretching), 1590, 1570, 1490, 1465 (C=C ring stretch), 2960 (methyl CH stretch), 1262 (asymmetric C-O-C stretching), 1019 (symmetric C-O-C stretching), 1283 (N-N=C); ¹H NMR δ (ppm): 7.24 (d, 2H, C-2 & C-6 of Ar), 6.68 (d, 1H, C-4 of Ar), 7.88 (s, 1H, C-4 of Ar'), 7.96 (s, 1H, C-6 of Ar'), 6.28 (s, 2H, NH₂), 3.84 (s, 6H, OCH₃); MS *m/z*: 511 M⁺, 513 M⁺², 515 M⁺⁴; Anal. Calcd. (%) for C₁₇H₁₃N₅O₂S Br₂: C, 39.94; H, 2.56; N, 13.70; S, 6.27. Found: C, 39.86; H, 2.56; N, 13.68; S, 6.24.

3-(3,4,5-trimethoxy phenyl)-6-(2-amino-3, 5-dibromo phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (14c)

Yield: 48%; m.p: 202 °C; IR (KBr) ν (cm⁻¹): 3273 (NH stretching), 3090, 3047 (aromatic CH stretching), 1612 (C=N stretching), 1585, 1575, 1484, 1436 (C=C ring stretch), 2964 (methyl CH stretch), 1290 (N-N=C); ¹H NMR δ (ppm): 7.32 (s, 2H, C-2 & C-6 of Ar), 7.86 (s, 1H, C-4 of Ar'), 7.94 (s, 1H, C-6 of Ar'), 6.28 (s, 2H, NH₂), 3.88 (s, 9H, OCH₃); MS *m/z*: 541 M⁺, 543 M⁺², 545 M⁺⁴; Anal. Calcd. (%) for C₁₈H₁₅N₅O₃S Br₂: C, 39.95; H, 2.79; N, 12.94; S, 5.92. Found: C, 40.07; H, 2.81; N, 12.86; S, 5.87.

3-(4-pyridinyl)-6-(2-amino-3,5-dibromophenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (14d)

Yield: 43%; m.p: 214 °C;IR (KBr) ν (cm⁻¹): 3280 (NH stretching), 3074 (aromatic CH stretching), 1618 (C=N stretching), 1585, 1554 (C=C ring stretch), 1280 (N-N=C); ¹H NMR δ (ppm): 8.04 (d, 1H, C-3 & C-5 of Ar), 8.7 (d, 1H, C-2 & C-6 of Ar), 7.86 (s, 1H, C-4 of Ar'), 7.92 (s, 1H, C-6 of Ar'), 6.28 (s, 2H, NH₂); MS *m/z*: 452 M⁺, 454 M⁺², 456 M⁺⁴; Anal. Calcd. (%) for C₁₄H₈N₆S Br₂: C, 37.19; H, 1.78; N, 18.59; S, 7.09. Found: C, 37.12; H, 1.79; N, 18.54; S, 7.69.

3-(3,4-dimethoxy phenyl)-6-(2-nitro-4-methyl phenyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (15a)

Yield: 65%; m.p: 194-196 °C;IR (KBr) ν (cm⁻¹): 3076 (aromatic CH stretching), 1613 (C=N stretching), 1586, 1485, 1451 (C=C ring stretch), 2966, 2933 (methyl CH stretch), 1266 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 1284 (N-N=C), 1525 (asymmetric Ar-NO₂ stretch), 1346 (symmetric Ar-NO₂ stretch); ¹H NMR δ (ppm): 7.12 (d, 1H, C-5 of Ar), 7.54 (s, 1H, C-2 of Ar), 7.70 (d, 1H, C-6 of Ar), 8.22 (s, 1H, C-3 of Ar'), 7.84 (d, 1H, C-5 of Ar'), 7.95 (d, 1H, C-6 of Ar'), 3.80 (s, 6H, OCH₃), 2.82 (s, 3H, CH₃ of Ar'); MS *m/z*: 397 M⁺; Anal. Calcd. (%) For C₁₈H₁₅N₅O₄S: C, 54.40; H, 3.80; N, 17.62; S, 8.07. Found: C, 54.32; H, 3.82; N, 17.58; S, 8.10.

3-(3,5-dimethoxy phenyl)-6-(2-nitro-4-methyl phenyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (15b)

Yield: 67%; m.p: 187 °C; IR (KBr) ν (cm⁻¹): 3075 (aromatic CH stretching), 1609 (C=N stretching), 1586, 1554, 1484, 1453 (C=C ring stretch), 2963, 2930 (methyl CH stretch), 1265 (asymmetric C-O-C stretching), 1027 (symmetric C-O-C stretching), 1286 (N-N=C), 1524 (asymmetric Ar-NO₂ stretch), 1345 (symmetric Ar-NO₂ stretch); ¹H NMR δ (ppm): 7.28 (d, 2H, C-2 & C-6 of Ar), 6.68 (d, 1H, C-4 of Ar), 8.22 (s, 1H, C-3 of Ar'), 7.84 (d, 1H, C-5 of Ar'), 7.95 (d, 1H, C-6 of Ar'), 3.84 (s, 6H, OCH₃), 2.82 (s, 3H, CH₃ of Ar'); MS *m/z*: 397 M⁺; Anal. Calcd. (%) for C₁₈H₁₅N₅O₄S: C, 54.40; H, 3.80; N, 17.62; S, 8.07. Found: C, 54.47; H, 3.78; N, 17.57; S, 8.04.

3-(3,4,5-trimethoxy phenyl)-6-(2-nitro-4-methyl phenyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (15c)

Yield: 63%; m.p: 174-176 °C; IR (KBr) ν (cm⁻¹): 3077 (aromatic CH stretching), 1618 (C=N stretching), 1589, 1554, 1483, 1455 (C=C ring stretch), 1259 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching), 2965, 2928 (methyl CH stretch), 1523 (asymmetric Ar-NO₂ stretch), 1343 (symmetric Ar-NO₂ stretch); ¹H NMR δ (ppm): 7.34 (s, 2H, C-2 & C-6 of Ar), 8.20 (s, 1H, C-3 of Ar'), 7.84 (d, 1H, C-5 of Ar'), 7.96 (d, 1H, C-6 of Ar'), 3.86 (s, 9H, OCH₃), 2.80 (s, 3H, CH₃ in Ar'); MS *m/z*: 427 M⁺; Anal. Calcd. (%) for C₁₉H₁₇N₅O₅S: C, 53.39; H, 4.01; N, 16.38; S, 7.50. Found: C, 53.32; H, 3.97; N, 16.46; S, 7.47.

3-(4-pyridinyl)-6-(2-nitro-4-methyl phenyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (15d)

Yield: 65%; m.p: 206 °C; IR (KBr) ν (cm⁻¹): 3085 (aromatic CH stretching), 1611 (C=N stretching), 1573, 1562 (C=C ring stretch), 2960, 2842 (methyl CH stretch), 1530 (asymmetric Ar-NO₂ stretch), 1349 (symmetric Ar-NO₂ stretch); ¹H NMR δ (ppm): 8.12 (d, 1H, C-3 & C-5 of Ar), 8.86 (d, 1H, C-2 & C-6 of Ar), 8.22 (s, 1H, C-3 of Ar'), 7.84 (d, 1H, C-5 of Ar'), 7.94 (d, 1H, C-6 of Ar'), 7.86 (d, 2H of Ar'), 2.80 (s, 3H, CH₃ of Ar'); MS *m/z*: 338 M⁺; Anal. Calcd. (%) for C₁₅H₁₀N₆O₂S: C, 53.25; H, 2.98; N, 24.84; S, 9.48. Found: C, 53.18; H, 2.98; N, 24.76; S, 9.45.

3-(3,4-dimethoxy phenyl)-6-[1-(2,4-dichloro phenoxy) ethyl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (16a)

Yield: 56%; m.p: 78 °C; IR (KBr) ν (cm⁻¹): 3078 (aromatic CH stretching), 1612 (C=N stretching), 1585, 1550 (C=C ring stretch), 2954, 2946 (methyl CH stretch), 1260 (asymmetric C-O-C stretching), 1022 (symmetric C-O-C stretching), 1281 (N-N=C); ¹H NMR δ (ppm): 7.16 (d, 1H, C-5 of Ar), 7.54 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 7.86 (s, 1H, C-3' of Ar), 7.76 (s, 1H, C-5' of Ar), 6.92 (d, 1H, C-6' of Ar'), 5.80 (q, 1H, CH in -CH-CH₃), 1.84 (d, 3H of CH₃ in -CH-CH₃), 3.80 (s, 6H, OCH₃); MS *m/z*: 451 M⁺, 453 M⁺, 455 M⁺; Anal. Calcd. (%) for C₁₉H₁₆N₄O₃S Cl₂: C, 50.56; H, 3.57; N, 12.41; S, 7.10. Found: C, 50.67; H, 3.59; N, 12.38; S, 7.07.

3-(3,5-dimethoxy phenyl)-6-[1-(2,4-dichloro phenoxy) ethyl]-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (16b)

Yield: 56%; m.p: 70 °C; IR (KBr) ν (cm⁻¹): 3085 (aromatic CH stretching), 1611 (C=N stretching), 1581, 1549, 1475, 1439 (C=C ring stretch), 2981, 2934 (methyl CH stretch), 1264 (asymmetric C-O-C stretching), 1028 (symmetric C-O-C stretching), 1280 (N-N=C); ¹H NMR δ (ppm): 7.2 (d, 2H, of Ar), 6.7 (d, 1H, of Ar), 7.86 (s, 1H, C-3' of Ar), 7.76 (s, 1H, C-5' of Ar), 6.92 (d, 1H, C-6' of Ar'), 5.80 (q, 1H, CH in -CH-CH₃), 1.84 (d, 3H of CH₃ in -CH-CH₃), 3.84 (s, 6H, OCH₃); MS *m/z*: 451 M⁺, 453 M⁺, 455 M⁺; Anal. Calcd. (%) for C₁₉H₁₆N₄O₃S Cl₂: C, 50.56; H, 3.57; N, 12.41; S, 7.10. Found: C, 50.68; H, 3.56; N, 12.38; S, 7.07.

3-(3,4,5-trimethoxy phenyl)-6-[1-(2,4-dichlorophenoxy) ethyl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (16c)

Yield: 52%; m.p: 80 °C; IR (KBr) ν (cm⁻¹): 3069 (aromatic CH stretching), 1613 (C=N stretching), 1587, 1525, 1485, 1451 (C=C ring stretch), 2974, 2865 (methyl CH stretch), 1261 (asymmetric C-O-C stretching), 1017 (symmetric C-O-C stretching), 1282 (N-N=C); ¹H NMR δ (ppm): 7.34 (s, 2H, C-2 & C-6 of Ar), 7.86 (s, 1H, C-3' of Ar), 7.74 (d, 1H, C-5' of Ar), 6.92 (d, 1H, C-6' of Ar'), 5.80 (q, 1H, CH in -CH-CH₃), 1.84 (d, 3H of CH₃ in -CH-CH₃), 3.86 (s, 9H, OCH₃); MS *m/z*: 481 M⁺, 483 M⁺², 485 M⁺⁴; Anal. Calcd. (%) for C₂₀H₁₈N₄O₄S Cl₂: C, 49.90; H, 3.77; N, 11.64; S, 6.66. Found: C, 49.84; H, 3.76; N, 11.63; S, 6.68.

3-(4-pyridinyl)-6-[1-(2,4-dichlorophenoxy)ethyl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole(16d)

Yield: 54%; m.p: 148 °C; IR (KBr) ν (cm⁻¹): 3075 (aromatic CH stretching), 1610 (C=N stretching), 1580, 1565 (C=C ring stretch), 1282 (N-N=C); ¹H NMR δ (ppm): 8.04 (d, 1H, C-3 & C-5 of Ar), 8.72 (d, 1H, C-2 & C-6 of Ar), 7.86 (s, 1H, C-3' of Ar), 7.76 (d, 1H, C-5' of Ar), 6.94 (d, 1H, C-6' of Ar'), 5.80 (q, 1H, CH in -CH-CH₃), 1.84 (d, 3H of CH₃ in -CH-CH₃); MS *m/z*: 392 M⁺, 394 M⁺², 396 M⁺⁴; Anal. Calcd. (%) for C₁₆H₁₁N₅O S Cl₂: C, 48.99; H, 2.83; N, 17.85; S, 8.17. Found: C, 49.09; H, 2.82; N, 17.78; S, 8.14.

General method for the preparation of 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole 17 (a-d)

An equimolecular mixture of substituted triazole (0.02 mol) and 2-furfuraldehyde (0.02 mol), DMF (30 mL) and a catalytic amount of *p*-toluenesulphonic acid (10 mg) were taken in a round bottom flask. Refluxed the mixture for about 10-12h. The reaction mixture was concentrated to half its volume and cooled to room temperature. Poured the cooled mixture gradually into crushed ice cubes with stirring. Allowed the mixture to stand, solid was separated. It was filtered, washed thoroughly with cold water, dried and recrystallized from hot ethanol. Similarly 18-20 (a-d) were synthesized and characterized.

3-(3,4-dimethoxy phenyl)-6-[2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (17a)

Yield: 55(%); m.p: 172°C;IR (KBr) ν (cm⁻¹): 3370 (NH stretching), 3056 (aromatic CH stretching), 1618 (C=N stretching), 1580, 1535 (C=C ring stretch), 1264 (asymmetric C-O-C stretching), 1017 (symmetric C-O-C stretching); ¹H NMR δ (ppm): 7.1 (d, 1H of C-5 of Ar), 7.5 (s, 1H, C-2 of Ar), 7.68 (d, 1H, C-6 of Ar), 6.84 (d, 1H, C-3' of furan), 7.24 (m, 1H of C-4' of furan), 7.78 (d, 1H C-5' of furan), 5.56 (s, 1H, CH in -CH-NH), 6.20 (s, 1H of NH in -NH-CH), 3.84 (s, 6H, OCH₃); MS *m/z*: 330 M⁺; Anal. Calcd. (%) for C₁₅H₁₄N₄O₃S: C, 54.53; H, 4.27; N, 16.96; S, 9.71. Found: C, 54.46; H, 4.29; N, 16.92; S, 9.74.

3-(3,5-dimethoxy phenyl)-6-[2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (17b)

Yield: 52%; m.p: 160°C; IR (KBr) ν (cm⁻¹): 3350 (NH stretching), 3076 (aromatic CH stretching), 1617(C=N stretching), 1576, 1552, 1480 (C=C ring stretch), 1262 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching); ¹H NMR δ (ppm): 7.12 (s, 2H, C-2 & C-6 of Ar), 6.7 (s, 1H, C-4 of Ar), 6.90 (d, 1H, C-3' of furan), 7.24 (m, 1H of C-4' of furan), 7.76 (d, 1H C-5' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.18 (s, 1H of NH in -NH-CH), 3.80 (s, 6H, OCH₃); MS *m/z*: 330 M⁺; Anal. Calcd. (%) for C₁₅H₁₄N₄O₃S: C, 54.53; H, 4.27; N, 16.96; S, 9.71. Found: C, 54.62; H, 4.29; N, 17.03; S, 9.68.

3-(3,4,5-trimethoxy phenyl)-6-[2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (17c)

Yield: 59%; m. p: 172°C; IR (KBr) ν (cm⁻¹): 3328 (NH stretching), 3080 (aromatic CH stretching), 1620 (C=N stretching), 1580, 1552, 1484 (C=C ring stretch), 1258 (asymmetric C-O-C stretching), 1023 (symmetric C-O-C stretching); ¹H NMR δ (ppm): (d, 7.32 (s, 2H, C-2 & C-6 of Ar), 6.90 (d, 1H, C-3' of furan), 7.20 (m, 1H of C-4' of furan), 7.7 (d, 1H C-5' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 3.86 (s, 9H, OCH₃); MS m/z : 360 M⁺; Anal. Calcd. (%) for C₁₆H₁₆N₄O₄S: C, 53.32; H, 4.47; N, 15.55; S, 8.90. Found: C, 53.25; H, 4.48; N, 15.48; S, 8.86.

3-(4-pyridinyl)-6-[2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (17d)

Yield: 58%; m.p: 218°C; IR (KBr) ν (cm⁻¹): 3356 (NH stretching), 3082 (aromatic CH stretching), 1614 (C=N stretching), 1580, 1547 (C=C ring stretch), 1261 (asymmetric C-O-C stretching), 1020 (symmetric C-O-C stretching); ¹H NMR δ (ppm): 8.00 (d, 2H, C-2 & C-6 of Ar), 8.64 (d, H, C-3 & C-5 of Ar), 6.86 (d, 1H, C-3' of furan), 7.26 (m, 1H of C-4' of furan), 7.74 (d, 1H C-5' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.20 (s, 1H of NH in -NH-CH); MS m/z : 271 M⁺; Anal. Calcd. (%) for C₁₂H₉N₅OS: C, 53.13; H, 3.34; N, 25.81; S, 11.82. Found: C, 53.05; H, 3.34; N, 25.74; S, 11.85.

3-(3,4-dimethoxy phenyl)-6-[5-nitro-2-furanyl]- 5,6-dihydro- 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (18a)

Yield: 59%; m.p: 224°C; IR (KBr) ν (cm⁻¹): 3338 (NH stretching), 3086 (aromatic CH stretching), 1619 (C=N stretching), 1590, 1558 (C=C ring stretch), 1265 (asymmetric C-O-C stretching), 1017 (symmetric C-O-C stretching), 1527 (asymmetric NO₂ stretch), 1347 (symmetric NO₂ stretch); ¹H NMR δ (ppm): 7.12 (d, 1H of C-5 of Ar), 7.58 (s, 1H, C-2 of Ar), 7.74 (d, 1H, C-6 of Ar), 7.36 (d, 1H, C-3' of furan), 7.90 (d, 1H of C-4' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.20 (s, 1H of NH in -NH-CH), 3.82 (s, 6H, OCH₃); MS m/z : 375 M⁺; Anal. Calcd. (%) for C₁₅H₁₃N₅O₅S: C, 48.00; H, 3.49; N, 18.66; S, 8.54. Found: C, 48.13; H, 3.51; N, 18.62; S, 8.51.

3-(3,5-dimethoxy phenyl)-6-[5-nitro-2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (18b)

Yield: 56%; m.p: 218°C; IR (KBr) ν (cm⁻¹): 3350 (NH stretching), 3079 (aromatic CH stretching), 1615 (C=N stretching), 1584, 1547, 1492 (C=C ring stretch), 1258 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 1519 (asymmetric NO₂ stretch), 1348 (symmetric NO₂ stretch); ¹H NMR δ (ppm): 7.20 (s, 2H, C-2 & C-6 of Ar), 6.76 (s, 1H, C-4 of Ar), 7.40 (d, 1H, C-3' of furan), 7.94 (d, 1H of C-4' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 3.80 (s, 6H, OCH₃); MS m/z : 375 M⁺; Anal. Calcd. (%) for C₁₅H₁₃N₅O₅S: C, 48.00; H, 3.49; N, 18.66; S, 8.54. Found: C, 47.91; H, 3.51; N, 18.72; S, 8.48.

3-(3,4,5-trimethoxy phenyl)-6-[5-nitro-2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (18c)

Yield: 60%; m.p: 214°C; IR (KBr) ν (cm⁻¹): 3345 (NH stretching), 3084 (aromatic CH stretching), 1620 (C=N stretching), 1580, 1542, 1490 (C=C ring stretch), 1530 (asymmetric NO₂ stretch), 1340 (symmetric NO₂ stretch); ¹H NMR δ (ppm): 7.28 (s, 2H, C-2 & C-6 of Ar), 7.42 (d, 1H, C-3' of furan), 7.92 (d, 1H of C-4' of furan), 5.60 (s, 1H, CH in -CH-NH), 6.18 (s, 1H of NH in -NH-CH), 3.84 (s, 9H, OCH₃); MS m/z : 405 M⁺; Anal. Calcd. (%) for C₁₆H₁₅N₅O₆S: C, 47.40; H, 3.73; N, 17.28; S, 7.91. Found: C, 47.41; H, 3.76; N, 17.24; S, 7.87.

3-(4-pyridinyl)-6-[5-nitro-2-furanyl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (18d)

Yield: 57%; m.p: 234°C; IR (KBr) ν (cm⁻¹): 3327 (NH stretching), 3068 (aromatic CH stretching), 1620 (C=N stretching), 1590, 1560 (C=C ring stretch), 1526 (asymmetric NO₂ stretch), 1342 (symmetric NO₂ stretch); ¹H NMR δ (ppm): 8.00 (d, 2H, C-2 & C-6 of Ar), 8.64 (d, H, C-3 & C-5 of Ar), 7.40 (d, 1H, C-3' of furan), 7.92 (d, 1H of C-4' of furan), 5.58 (s, 1H, CH in -CH-NH), 6.16 (s, 1H of NH in -NH-CH); MS m/z : 316 M⁺; Anal. Calcd. (%) for C₁₂H₈N₆O₃S: C, 45.57; H, 2.55; N, 26.57; S, 10.14. Found: C, 45.48; H, 2.55; N, 26.62; S, 10.11.

3-(3,4-dimethoxy phenyl)-6-[pyrol-2-yl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (19a)

Yield: 53%; m.p: 176 °C; IR (KBr) ν (cm⁻¹): 3352 (NH stretching), 3070 (aromatic CH stretching), 1619 (C=N stretching), 1586, 1554 (C=C ring stretch), 1263 (asymmetric C-O-C stretching), 1019 (symmetric C-O-C stretching); ¹H NMR δ (ppm): 7.20 (d, 1H of C-5 of Ar), 7.58 (s, 1H, C-2 of Ar), 7.76 (d, 1H, C-6 of Ar), 6.42 (d, 1H, C-3' of pyrrole), 6.60 (m, 1H of C-4' of pyrrole), 7.04 (d, 1H of C-5' of pyrrole), 5.60 (s, 1H, CH in -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 9.8 (d, 1H, -NH of pyrrole), 3.80 (s, 6H, OCH₃); MS m/z : 329 M⁺; Anal. Calcd. (%) for C₁₅H₁₅N₅O₂S: C, 54.70; H, 4.59; N, 21.26; S, 9.74. Found: C, 54.62; H, 4.61; N, 21.18; S, 9.71.

3-(3,5-dimethoxy phenyl)-6-[pyrol-2-yl]- 5,6-dihydro-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazole (19b)

Yield: 50%; m.p: 162°C; IR (KBr) ν (cm⁻¹): 3365 (NH stretching), 3083 (aromatic CH stretching), 1617(C=N stretching), 1586, 1550, 1470 (C=C ring stretch), 1257 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching); ¹H NMR δ (ppm): 7.26 (s, 2H, C-2 & C-6 of Ar), 6.80 (s, 1H, C-4 of Ar), 6.46 (d, 1H, C-3' of pyrrole), 6.60 (m, 1H of C-4' of pyrrole), 7.06 (d, 1H of C-5' of pyrrole), 5.60 (s, 1H, CH in -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 9.6 (d, 1H, -NH of pyrrole), 3.80 (s, 6H, OCH₃); MS m/z : 329 M⁺; Anal. Calcd. (%) for C₁₅H₁₅N₅O₂S: C, 54.70; H, 4.59; N, 21.26; S, 9.74. Found: C, 54.63; H, 4.60; N, 21.32; S, 9.71.

3-(3,4,5-trimethoxy phenyl)-6-[pyrol-2-yl]- 5,6-dihydro- 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (19c)

Yield: 55%; m.p: 180°C; IR (KBr) ν (cm⁻¹): 3348 (NH stretching), 3076 (aromatic CH stretching), 1615 (C=N stretching), 1580, 1568, 1490 (C=C ring stretch), 1259 (asymmetric C-O-C stretching), 1024 (symmetric C-O-C stretching); ¹H NMR δ (ppm): ¹H NMR δ (ppm): 7.34 (s, 2H, C-2 & C-6 of Ar), 6.42 (d, 1H, C-3' of pyrrole), 6.59 (m, 1H of C-4' of pyrrole), 7.06 (d, 1H of C-5' of pyrrole), 5.60 (s, 1H, CH in -CH-NH), 6.18 (s, 1H of NH in -NH-CH), 9.8 (d, 1H, -NH of pyrrole), 3.84 (s, 9H, OCH₃); MS m/z : 359 M⁺; Anal. Calcd. (%) for C₁₆H₁₇N₅O₃S: C, 53.47; H, 4.77; N, 19.49; S, 8.92. Found: C, 53.45; H, 4.77; N, 19.42; S, 8.87.

3-(4-pyridinyl)-6-[pyrol-2-yl]- 5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (19d)

Yield: 53%; m. p: 206°C; IR (KBr) ν (cm⁻¹): 3365 (NH stretching), 3086 (aromatic CH stretching), 1618 (C=N stretching), 1588, 1566 (C=C ring stretch); ¹H NMR δ (ppm): 7.96 (d, 2H, C-2 & C-6 of Ar), 8.68 (d, H, C-3 & C-5 of Ar), 6.40 (d, 1H, C-3' of pyrrole), 6.62 (m, 1H of C-4' of pyrrole), 7.04 (d, 1H of C-5' of pyrrole), 5.60 (s, 1H, CH in -CH-NH), 6.18 (s, 1H of NH in -NH-CH), 9.8 (d, 1H, -NH of pyrrole); MS m/z : 270 M⁺; Anal. Calcd. (%) for C₁₂H₁₀N₆S: C, 53.32; H, 3.73; N, 31.09; S, 11.86. Found: C, 53.25; H, 3.73; N, 31.14; S, 11.80.

3-(3,4-dimethoxy phenyl)-6-[N-methyl-pyrol-2-yl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (20a)

Yield: 57%; m.p: 184°C; IR (KBr) ν (cm⁻¹): 3364 (NH stretching), 3062 (aromatic CH stretching), 1610 (C=N stretching), 1580, 1553 (C=C ring stretch), 1266 (asymmetric C-O-C stretching), 1021 (symmetric C-O-C stretching), 2963, 2847 (methyl CH stretch); ¹H NMR δ (ppm): 7.24 (d, 1H of C-5 of Ar), 7.56 (s, 1H, C-2 of Ar), 7.72 (d, 1H, C-6 of Ar), 6.88 (d, 1H, C-5' of pyrrole), 6.56 (m, 1H, C-4' of pyrrole), 6.40 (d, 1H, C-3' of pyrrole), 5.62 (s, 1H, of -CH-NH), 6.20 (s, 1H of NH in -NH-CH), 3.56 (s, 3H of N-CH₃), 3.82 (s, 6H, OCH₃); MS *m/z*: 343 M⁺; Anal. Calcd. (%) for C₁₆H₁₇N₅O₂S: C, 55.96; H, 4.99; N, 20.39; S, 9.34. Found: C, 56.10; H, 5.01; N, 20.31; S, 9.31.

3-(3,5-dimethoxyphenyl)-6-[N-methyl-pyrol-2-yl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole(20b)

Yield: 52%; m.p: 174°C; IR (KBr) ν (cm⁻¹): 3364 (NH stretching), 3058 (aromatic CH stretching), 1615 (C=N stretching), 1589, 1565, 1480 (C=C ring stretch), 1258 (asymmetric C-O-C stretching), 1025 (symmetric C-O-C stretching), 2958, 2849 (methyl CH stretch); ¹H NMR δ (ppm): 7.22 (s, 2H, C-2 & C-6 of Ar), 6.76 (s, 1H, C-4 of Ar), 6.9 (d, 1H, C-5' of pyrrole), 6.52 (m, 1H, C-4' of pyrrole), 6.38 (d, 1H, C-3' of pyrrole), 5.48 (s, 1H, of -CH-NH), 6.18 (s, 1H of NH in -NH-CH), 3.60 (s, 3H of N-CH₃), 3.82 (s, 6H, OCH₃); MS *m/z*: 343 M⁺; Anal. Calcd. (%) for C₁₆H₁₇N₅O₂S: C, 55.96; H, 4.99; N, 20.39; S, 9.34. Found: C, 56.05; H, 5.01; N, 20.34; S, 9.32.

3-(3,4,5-trimethoxyphenyl)-6-[N-methyl-pyrol-2-yl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (20c)

Yield: 61%; m. p: 162°C; IR (KBr) ν (cm⁻¹): 3345 (NH stretching), 3072 (aromatic CH stretching), 1616 (C=N stretching), 1587, 1549, 1480 (C=C ring stretch), 1264 (asymmetric C-O-C stretching), 1022 (symmetric C-O-C stretching), 2965, 2850 (methyl CH stretch); ¹H NMR δ (ppm): 7.3 (s, 2H, C-2 & C-6 of Ar), 7.06 (d, 1H, C-5' of pyrrole), 6.82 (m, 1H, C-4' of pyrrole), 6.64 (d, 1H, C-3' of pyrrole), 5.50 (s, 1H, of -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 3.60 (s, 3H of N-CH₃), 3.86 (s, 9H, OCH₃); MS *m/z*: 373 M⁺; Anal. Calcd. (%) for C₁₇H₁₉N₅O₃S: C, 54.68; H, 5.13; N, 18.75; S, 8.59. Found: C, 54.61; H, 5.13; N, 18.67; S, 8.61.

3-(4-pyridinyl)-6-[N-methyl-pyrol-2-yl]-5,6-dihydro-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (20d)

Yield: 59%; m. p: 200°C; IR (KBr) ν (cm⁻¹): 3369 (NH stretching), 3045 (aromatic CH stretching), 1614 (C=N stretching), 1590, 1563 (C=C ring stretch), 2964, 2840 (methyl CH stretch); ¹H NMR δ (ppm): 8.02 (d, 2H, C-2 & C-6 of Ar), 8.66 (d, H, C-3 & C-5 of Ar), 6.86 (d, 1H, C-5' of pyrrole), 6.56 (m, 1H, C-4' of pyrrole), 6.38 (d, 1H, C-3' of pyrrole), 5.48 (s, 1H, of -CH-NH), 6.16 (s, 1H of NH in -NH-CH), 3.50 (s, 3H of N-CH₃), MS *m/z*: 284 M⁺; Anal. Calcd. (%) for C₁₃H₁₂N₆S: C, 54.91; H, 4.25; N, 29.56; S, 11.28. Found: C, 54.81; H, 4.22; N, 29.52; S, 11.25.

Results and Discussion

In the IR spectra of the cyclized products showed absorption band at 3270-3290cm⁻¹ due to NH functional group and the weak broad absorption band around 2580cm⁻¹ due to SH group were absent. This confirmed the involvement of NH₂ and SH groups of the parent amino mercapto triazole in the ring formation. An absorption band was observed for all the synthesized compounds in the range of 3060-3090 cm⁻¹ may be attributed for aromatic stretching vibration, while that seen at 1610-1614cm⁻¹ corresponds to C=N linkage. Thus, the formation of iminomethine functional group in the compound was indicated.

In the ^1H NMR spectra of synthesized compound, the peaks due to NH_2 and SH , which were present in the amino mercapto triazole were absent that further confirmed the involvement of these functional groups in the cyclization of triazole to triazolo thiadiazoles. Similarly the absence of SH proton and the down fielding of NH_2 protons (integration for one proton) in the ^1H NMR spectra established that $-\text{CHO}$ group of the aromatic aldehydes reacted with $-\text{SH}$ & $-\text{NH}_2$ groups of triazoles and thus converted to dihydro triazolo thiadiazoles (17-20). The ^1H NMR, mass spectra, IR and elemental analysis supported the structure of various synthesized triazolo thiadiazoles and their dihydro analogues.

The antimicrobial results showed that some of the compounds are active against the tested microbes. It can be concluded that none of the prepared compounds were superior to positive controls against various tested microbial strains, but was interesting to note that compounds 8d, 9a, 9b, 9d, 14d & 16d were very sensitive to all the tested organisms comparable to the standards used at the concentration of $30\mu\text{g/mL}$. Antimicrobial effects of the some of the synthesized compounds were reported in Table 3 & 4 as zone of inhibition against various bacterial and fungal strains respectively.

Anti-inflammatory and analgesic activity screening indicated that some of the tested compound 10d, 12d, 14a, 14b, 14d, 16a, 16b and 16d showed good anti-inflammatory and analgesic activities. Other compounds had moderate anti-inflammatory and analgesic activities. Anti-inflammatory and analgesic effects of the newly synthesized compounds were reported in Table 1 & 2 respectively.

Table 1. Anti-inflammatory activity of compounds

Compd	Change in paw volume (in mL) after ($\pm\text{SE}$) [#]				Percentage inhibition of oedema volume after			
	1h	2h	3h	4h	1h	2h	3h	4h
8a	0.71 \pm 0.02	0.98 \pm 0.03	1.39 \pm 0.02	1.52 \pm 0.02	11.4	16.2	20.7	26.5
8b	0.73 \pm 0.02	1.02 \pm 0.04	1.41 \pm 0.03	1.56 \pm 0.03	8.8	12.9	19.5	24.6
8c	0.74 \pm 0.02	1.00 \pm 0.06	1.45 \pm 0.04	1.64 \pm 0.03	7.8	13.9	17.4	20.5
8d	0.71 \pm 0.02	0.97 \pm 0.05	1.36 \pm 0.02	1.52 \pm 0.02	11.3	16.8	22.3	26.4
10a	0.80 \pm 0.02	1.07 \pm 0.07	1.43 \pm 0.02	1.66 \pm 0.02	11.2	16.5	20.7	26.4
10b	0.79 \pm 0.05	1.07 \pm 0.03	1.42 \pm 0.03	1.65 \pm 0.04	12.3	16.9	21.1	26.8
10c	0.82 \pm 0.05	1.10 \pm 0.07	1.49 \pm 0.02	1.77 \pm 0.03	8.6	14.0	17.1	21.5
10d	0.77 \pm 0.02	1.02 \pm 0.02	1.32 \pm 0.03	1.53 \pm 0.04	14.9*	20.5*	26.7*	31.9*
12a	0.76 \pm 0.02	1.00 \pm 0.02	1.32 \pm 0.03	1.58 \pm 0.07	15.6*	22.1*	26.8*	29.8*
12b	0.77 \pm 0.04	1.01 \pm 0.03	1.32 \pm 0.04	1.61 \pm 0.05	14.7*	21.2*	26.4*	28.5*
12c	0.78 \pm 0.04	1.06 \pm 0.02	1.39 \pm 0.03	1.70 \pm 0.03	13.3*	17.1	22.8	24.4
12d	0.74 \pm 0.03	0.93 \pm 0.02	1.19 \pm 0.05	1.44 \pm 0.02	17.8	27.9	33.9**	36.2**
14a	0.61 \pm 0.02	0.83 \pm 0.03	1.08 \pm 0.03	1.33 \pm 0.03	17.4***	23.5*	29.6*	32.8*
14b	0.60 \pm 0.03	0.83 \pm 0.02	1.10 \pm 0.07	1.36 \pm 0.05	17.8***	23.2*	27.9*	31.6*
14c	0.62 \pm 0.03	0.89 \pm 0.03	1.17 \pm 0.05	1.46 \pm 0.023	15.3**	18.3	23.8	26.4
14d	0.58 \pm 0.02	0.79 \pm 0.06	1.04 \pm 0.02	1.26 \pm 0.02	20.3***	26.7**	32.3*	36.6**
16a	0.62 \pm 0.02	0.85 \pm 0.05	1.09 \pm 0.02	1.35 \pm 0.04	15.9**	21.7*	29.0*	32.1*
16b	0.61 \pm 0.02	0.82 \pm 0.04	1.07 \pm 0.02	1.32 \pm 0.02	16.9**	24.7**	29.9*	33.2*
16c	0.63 \pm 0.04	0.86 \pm 0.02	1.16 \pm 0.02	1.45 \pm 0.02	14.4*	20.6*	24.0	26.8
16d	0.55 \pm 0.03	0.82 \pm 0.02	1.07 \pm 0.05	1.30 \pm 0.04	18.9***	24.3**	30.1*	34.6**
Phenyl butazone	0.72 \pm 0.03	0.92 \pm 0.03	0.97 \pm 0.04	1.00 \pm 0.00	21.2***	33.5***	40.8***	48.0***

= \pm Standard error ; * = $P < 0.05$; ** = $P < 0.01$; *** = $P < 0.001$; For all other comparison $P > 0.05$.

Table 2. Analgesic activities of compounds

Compd	Reaction time (sec) after drug administration			Percent increase in reaction time		
	30 min± SE [#]	60 min± SE [#]	90 min ± SE [#]	30min	60min	90min
8d	5.98±0.43	6.30±0.43	6.64±0.21	19.2	23.3*	27.3*
9d	7.81±0.31	8.37±0.34	8.68±0.45	19.0	24.4*	27.1*
10d	8.23±0.33	8.84±0.55	9.29±0.45	19.1	24.7*	28.3*
12a	8.70±0.73	9.27±0.43	9.73±0.35	17.7	22.8	26.4*
12b	7.23±0.24	8.02±0.45	8.46±0.34	14.8	23.2*	27.2*
12c	7.47±0.56	7.77±0.50	8.63±0.61	11.6	19.1	23.5
12d	3.98±0.33	4.29±0.60	4.57±0.31	20.5	26.2**	30.7*
14a	8.34±0.34	9.20±0.21	10.03±0.40	20.1	27.6**	33.6**
14b	8.54±0.52	9.08±0.45	9.48±0.60	23.9	28.4**	31.4**
14c	9.53±0.34	10.16±0.42	10.52±0.34	21.3	26.2**	28.7*
14d	8.39±0.15	9.21±0.42	10.09±0.45	26.6	33.1***	38.9**
15d	4.44±0.47	4.75±0.56	5.06±0.37	17.6	22.9	27.7
16a	5.60±0.15	6.26±0.42	6.63±0.45	22.7	30.8**	34.7**
16b	9.60±0.33	10.69±0.48	11.42±0.17	20.2	28.3*	32.9**
16c	7.19±0.34	8.13±0.37	8.47±0.21	16.6	26.2*	29.2*
16d	5.91±0.34	6.89±0.42	7.28±0.34	23.9	34.7***	38.2**
17d	6.24±0.17	6.92±0.21	7.84±0.40	5.68	15.18	26.14
18d	6.17±0.34	6.85±0.56	8.70±0.37	5.34	15.68	26.85
diclofenac sodium	4.74±0.50	5.58±0.43	7.33±0.21	26.2***	37.3***	52.3***

[#] = Standard error; * = P<0.05. ** = P<0.01. *** = P<0.001. For all other comparison P>0.05.

Pharmacology

Anti-inflammatory activity

All the synthesized compounds were evaluated for their anti-inflammatory activity against carrageenan-induced acute paw oedema in albino rats (Wistar strain) weighing 150-200g^{15,16}. The animals were weighed and numbered into various groups and each group contained six animals. One group served as control and received 0.1mL of 1% gum acacia suspension orally. Group II served as standard and received phenylbutazone at a dose of 5mg/kg suspension in gum acacia orally. One hour after the administration of test compounds at a dose of 5mg/kg as suspension in gum acacia, 0.1 mL of 1% carrageenan in normal saline was given subcutaneously to the sub plantar region of right hind paw. The paw volume was measured immediately ('0' h) and after 1, 2, 3 and 4th h respectively by using plethysmograph. The amount of oedema in the drug-treated groups was compared in relation to the control group with the corresponding time intervals. The percentage of inhibition by the drugs was calculated by using the formula,

$$\text{Percentage inhibition} = 100 (1 - V_{\text{test}} / V_{\text{control}}),$$

Where V_{test} = mean increase in paw volume of drug treated group;

V_{control} = mean increase in paw volume of control group.

The results were expressed as percentage inhibition of oedema over the untreated control group.

Table 3. Antifungal activities of compounds

Compd	<i>C. albicans</i> ¹			<i>A. niger</i> ²		
	10, µg /mL ±SD*	20, µg /mL ±SD*	30, µg /mL ±SD*	10, µg /mL ±SD*	20, µg /mL ±SD*	30, µg/mL ±SD*
4a	5.64±1.16	12.84±1.73	18.78±1.53	6.04±0.58	11.63±0.58	17.58±1.16
4b	5.82±0.58	11.37±0.58	17.95±1.73	6.14±1.16	11.54±1.53	16.72±0.58
4d	6.27±0.58	14.84±1.16	19.36±1.53	5.92±0.58	11.00±0.00	17.67±0.58
5a	6.18±1.16	13.82±0.58	18.75±0.61	5.62±0.47	12.62±0.58	18.54±0.27
5b	5.84±0.53	12.62±0.58	19.00±2.00	6.00±1.00	13.46±0.58	17.42±1.16
5d	5.48±0.58	12.00±1.00	17.48±1.53	6.25±0.58	13.00±1.00	16.72±0.27
6a	6.48±0.58	13.92±1.73	18.00±1.00	6.40±0.61	12.85±0.58	19.10±1.53
6b	6.14±0.58	13.66±0.47	17.82±0.27	6.32±0.61	13.00±1.00	19.00±0.00
6d	5.78±0.58	11.00±1.00	19.24±1.53	6.14±0.58	12.00±1.00	19.10±0.58
7d	5.34±0.58	10.00±2.00	17.28±1.53	5.14±0.58	9.48±0.58	16.84±0.58
8a	7.14±0.47	13.72±0.58	19.28±0.47	6.64±0.58	11.84±1.73	18.42±1.16
8b	6.82±0.58	12.88±0.61	19.36±0.61	7.23±0.58	13.00±0.00	18.38±0.27
8c	5.66±0.47	11.62±0.58	17.28±1.73	6.12±0.47	10.68±0.58	15.62±1.16
8d	7.26±0.58	14.00±2.00	21.86±1.53	7.38±0.27	14.26±0.58	20.66±0.58
9a	7.68±0.58	14.46±1.16	21.68±1.16	6.68±0.58	12.57±0.58	20.48±1.73
9b	8.14±0.47	14.75±0.58	21.72±1.16	7.14±0.58	12.44±0.58	20.96±0.58
9c	6.14±0.61	11.62±0.58	17.36±0.58	5.84±1.16	10.74±1.53	17.85±0.27
9d	8.82±0.58	16.58±0.58	23.76±1.53	7.36±0.58	13.00±0.00	22.66±0.58
10a	5.44±0.58	9.26±0.58	17.16±1.16	5.38±1.73	10.12±0.61	16.94±0.61
10b	5.76±0.58	9.38±0.47	18.00±2.00	5.16±0.47	9.18±0.58	17.36±1.53
10d	6.12±0.58	10.83±0.61	19.47±1.53	5.62±0.58	10.86±0.61	18.74±0.58
11a	4.35±0.58	8.72±1.16	16.73±1.16	4.57±2.08	9.24±1.16	15.26±2.08
11b	4.69±0.58	9.16±2.08	16.16±1.16	4.93±0.58	8.58±1.16	15.78±1.53
11d	5.14±0.58	9.86±1.16	17.14±1.53	5.85±0.58	11.00±2.00	16.42±0.58
12a	5.86±0.58	11.48±1.16	17.47±1.53	5.18±0.58	11.12±0.17	16.94±0.58
12b	6.10±0.58	11.24±0.47	17.22±1.53	5.24±0.58	10.62±0.27	17.12±0.58
12d	6.38±0.58	13.37±0.27	19.72±0.27	5.64±0.58	13.86±0.61	19.16±1.16
13d	4.72±0.27	7.37±1.73	12.46±1.16	4.82±0.58	9.38±0.61	14.35±0.27
14a	6.72±0.47	13.85±0.61	19.06±0.61	6.41±0.58	12.35±0.47	18.49±0.58
14b	6.88±1.73	12.69±0.58	19.28±0.27	6.05±0.58	13.06±0.27	17.35±1.53
14c	5.14±0.61	10.17±0.27	16.36±0.47	4.76±1.73	8.49±1.16	14.06±0.61
14d	7.96±0.58	14.00±1.00	20.31±1.16	8.16±0.58	15.72±0.47	19.84±0.58
15d	5.62±0.58	9.38±0.61	16.49±0.27	6.86±0.58	9.63±1.73	17.54±0.58
16a	7.36±0.61	11.92±1.16	18.17±1.53	7.46±0.47	12.15±0.61	18.12±0.58
16b	7.42±0.58	11.88±0.47	19.02±0.27	7.56±0.58	13.00±0.00	18.30±0.27
16c	5.84±0.27	9.63±1.73	16.47±0.58	5.63±0.561	11.37±0.27	15.10±0.61
16d	8.72±0.47	13.96±1.16	21.36±0.61	7.85±0.27	13.94±0.61	20.82±0.27
Griseofulvin	-	-	24.67±1.16	-	-	23.14±2.00

*SD = Standard Deviation; 1 = *Candida albicans*; 2 = *Aspergillus niger*

Table 4. Antibacterial activity of compounds.

Compd	<i>E.coli</i> ¹			<i>P. aeruginosa</i> ²			<i>B. subtilis</i> ³			<i>S. aureus</i> ⁴		
	10µg/mL ±SD*	20µg/mL ±SD*	30µg/mL ±SD*	10µg/mL ±SD*	20µg/mL ±SD*	30µg/mL ±SD*	10µg/mL ±SD*	20µg/mL ±SD*	30µg/mL ±SD*	10µg/mL ±SD*	20µg/mL ±SD*	30µg/mL ±SD*
4a	6.86±1.73	11.72±2.52	16.52±2.65	6.72±1.16	11.38±0.58	15.49±0.58	6.82±0.47	11.15±1.16	16.16±1.53	5.82±0.58	10.12±0.58	16.36±0.58
4b	6.08±0.58	11.28±0.47	16.86±1.16	5.92±0.61	10.85±0.58	16.04±1.16	5.76±0.58	10.24±1.53	15.92±0.47	5.12±0.26	10.26±0.61	16.74±0.58
4c	5.16±1.16	9.84±1.53	14.18±2.52	6.10±0.58	10.63±0.58	14.48±0.58	4.80±0.58	9.02±1.16	14.00±1.00	5.04±0.58	10.36±1.16	16.60±0.58
4d	7.64±0.26	13.18±0.58	17.36±0.45	7.12±0.26	12.04±1.16	17.26±2.09	6.16±0.61	11.84±0.58	16.86±1.53	6.18±0.58	12.69±0.17	17.48±0.58
5a	5.16±1.73	9.12±2.52	16.67±2.89	5.31±1.16	10.26±1.53	16.11±0.58	7.06±1.71	11.10±0.61	16.38±0.45	6.89±0.58	12.06±0.17	16.10±1.16
5b	5.25±1.15	8.80±0.00	16.00±0.00	5.26±0.57	10.12±1.15	16.05±1.15	6.29±.57	10.18±1.15	16.12±0.57	6.72±0.57	11.68±0.57	16.60±0.57
5c	5.84±0.58	8.19±0.58	14.20±1.53	4.67±0.45	9.10±0.58	15.53±1.16	5.48±1.16	9.63±0.58	15.80±1.73	6.78±0.58	11.29±0.61	16.00±2.00
5d	6.28±0.45	10.48±0.58	17.00±1.00	6.00±0.00	11.84±0.17	16.82±1.73	7.38±1.16	12.48±0.17	17.10±1.53	7.10±0.58	13.73±0.63	17.92±0.26
6a	8.28±0.26	14.48±0.58	18.78±0.45	7.82±0.26	13.27±1.16	18.71±2.09	7.68±0.61	13.06±0.58	18.80±1.53	7.21±0.58	13.19±0.17	18.12±0.58
6b	7.85±1.73	14.36±2.52	18.64±2.89	7.70±1.16	14.10±1.53	18.16±0.58	7.40±1.71	13.26±0.61	18.66±0.45	6.96±0.58	12.61±0.17	18.27±1.16
6c	7.22±1.16	13.96±0.47	16.72±0.21	6.90±0.58	12.92±1.16	16.73±2.09	7.10±1.16	12.50±1.73	16.82±0.45	6.48±0.17	12.10±1.16	17.85±0.26
6d	8.74±0.58	15.27±1.16	19.41±0.58	8.17±2.09	14.15±0.17	19.10±0.58	8.14±1.53	14.10±0.45	19.79±1.71	8.16±0.58	14.10±1.16	19.12±0.58
8a	6.39±2.09	12.23±0.17	19.21±0.58	7.02±0.26	12.48±1.16	19.11±0.58	7.12±1.53	13.84±0.58	18.63±1.16	6.98±0.58	13.70±1.16	18.58±0.26
8b	6.72±0.61	12.82±1.16	19.67±2.09	6.93±0.45	12.19±0.58	19.39±0.61	7.19±0.47	13.92±0.17	18.91±0.63	7.05±0.26	13.61±1.16	18.14±1.53
8c	6.06±2.09	11.73±1.16	18.68±0.47	6.15±1.16	12.02±2.09	18.52±0.26	6.48±1.16	12.71±0.58	16.85±0.63	6.82±0.45	12.72±1.16	17.36±0.61
8d	7.48±0.58	14.78±0.47	20.19±0.17	7.79±0.61	13.78±0.47	20.59±0.26	7.82±1.17	14.55±0.58	20.38±1.16	7.82±0.63	14.66±0.17	19.23±0.58
9a	8.10±0.45	14.65±1.17	19.67±1.16	8.68±1.16	14.92±0.58	19.52±1.73	7.78±1.16	14.12±1.16	19.16±1.53	7.29±2.09	14.11±0.61	19.25±0.17
9b	7.96±0.26	14.39±0.47	19.29±0.61	8.21±0.17	14.88±2.09	19.26±0.58	7.64±1.53	14.38±0.47	19.26±0.47	7.10±0.61	13.85±1.61	19.19±0.17
9c	7.08±0.47	13.85±0.58	18.80±1.16	7.85±1.16	14.19±0.58	18.83±0.58	6.90±1.16	13.81±0.58	18.78±0.47	6.82±0.58	13.57±0.58	17.95±1.73
9d	8.54±0.47	14.27±0.58	20.79±1.16	8.39±1.53	15.21±0.45	21.29±0.61	8.12±1.16	14.76±0.58	19.86±1.73	7.90±0.58	14.18±2.09	20.17±1.53
14a	7.14±0.26	13.72±1.16	17.92±0.58	6.82±0.58	12.88±0.61	18.10±2.09	6.97±1.53	12.28±0.45	18.19±1.16	6.49±0.47	12.37±1.16	18.24±0.58
14b	6.89±0.17	12.17±2.09	17.24±1.16	6.70±1.17	12.62±0.58	18.28±1.73	6.82±1.16	12.39±1.16	18.07±1.53	6.55±0.45	12.46±0.61	18.35±0.26
14c	6.15±0.58	11.27±0.45	16.93±0.61	5.96±0.58	12.05±0.45	17.85±1.16	6.18±0.17	11.48±0.47	17.21±1.53	5.79±.61	11.72±0.47	17.49±0.17
14d	7.37±0.61	13.89±0.58	18.21±1.16	7.38±1.73	13.48±0.58	19.71±0.21	7.80±1.16	13.60±0.58	19.38±0.61	7.12±0.58	13.70±0.58	19.81±0.47
16a	6.85±0.58	13.18±0.63	19.00±1.16	6.60±1.53	12.17±0.58	18.38±1.16	6.45±0.47	13.30±1.53	18.27±2.09	6.16±1.73	12.60±0.61	18.86±0.58
16b	6.71±1.17	12.85±1.16	18.19±1.16	6.16±1.53	12.43±0.58	18.45±0.45	6.17±1.16	13.11±1.53	18.28±1.73	6.02±0.47	12.91±0.61	18.66±0.58
16c	6.10±0.58	11.90±1.16	17.65±1.53	5.56±0.47	11.65±0.58	17.68±1.53	5.80±0.58	11.82±0.61	17.45±0.58	5.85±1.16	11.47±0.58	17.94±1.73
16d	7.12±0.26	13.36±0.58	19.26±0.47	7.19±0.45	13.28±0.17	19.10±1.73	7.31±0.58	13.27±0.47	19.10±1.53	6.86±0.47	12.90±2.09	18.15±0.26
18d	5.78±1.53	11.02± 2.09	16.85±1.16	6.12±1.53	11.82±0.58	17.14±0.58	6.25±1.16	11.52±1.16	17.23±1.73	6.11±0.61	11.51±0.47	17.48±0.58
Vancomycin	-	-	-	-	-	-	-	-	23.33±1.53	-	-	22.48±0.58
Amikacin	-	-	22.67±0.58	-	-	24.00±-1.00	-	-	-	-	-	-

*SD = Standard Deviation; # Zone of inhibition in mm; 1 = *Escherichia coli*; 2 = *Pseudomonas aeruginosa*; 3 = *Staphylococcus aureus*; 4 = *Bacillus subtilis*

Analgesic activity

All the compounds were tested for their analgesic activity using Eddy's hot plate technique¹⁷. Mice (Swiss strain) of either sex weighing between 25-35g were used for the experiment. In this method heat is used as a source of pain. Animals were individually placed on a hot plate maintained at constant temperature (55 °C) and the reaction of animals, such as paw licking or jump response (whichever appears first) was taken as the end point. A cut off - time of 15 seconds (sec) was taken as maximum analgesic response to avoid injury to the paws. Tested compounds and diclofenac sodium (standard) at a dose of 5mg/kg body weight in 1% gum acacia was given as suspension orally to animals and observed the reaction time of animals on the hot plate at 15, 30, 60, 90 and 120 minutes (min) after the compound administration. Percentage analgesic activity shown by the tested compounds is recorded in Table 2.

Antibacterial and antifungal activities

Applying the agar plate diffusion technique¹⁸ all of the newly synthesized compounds were screened *in vitro* for antibacterial activity against *Escherichia coli* (*E.coli*), *Pseudomonas aeruginosa* (*P. aeruginosa*) (Gram negative), *Staphylococcus aureus* (*S.aureus*), *Bacillus Subtilis* (*B.subtilis*) (Gram positive) at 10µg/mL, 20µg/mL, 30µg/mL concentrations respectively. Under identical conditions the positive control antibiotics Amikacin at 30µg/mL showed zone of inhibition 23-24mm for gram-negative organism and Vancomycin at 100µg/mL showed zone of inhibition 23mm for gram-positive organism. Similarly, the antifungal screening of the compounds were carried out *in vitro* by paper disc method against two fungi *Aspergillus niger* (*A.niger*) and *Candida albicans* (*C.albicans*) by using Griseofulvin (30µg/mL) as the positive control, which showed (23mm and 25mm respectively) as the zone of inhibition.

Acknowledgements

The authors are thankful to IISc, Bangalore, IIT, Chennai and STIC, Cochin, for the Spectral analysis. The authors are also thankful to the Chairman, Dept. of Chemistry, Kuvempu University, for providing laboratory facilities.

References

- 1 Colanceska-Ragenovic K, Dimoval V, Kakurinov V, Labor D and Molnar A B, *Molecules*, 2001, **6**, 815.
- 2 Labanauskas L, Udrenaitė E, Gaidelis P and Bruk tus A, *IL Farmaco*, 2004, **59**, 255.
- 3 Al-Soud Y A, Al-Dweri M N and Al-Masoudi N A, *IL Farmaco*, 2004, **59**, 775.
- 4 Foroumadi A, Mirzaei M and Shafiee A, *IL Farmaco*, 2001, **56**,621.
- 5 Jain S K and Mishra P, *Ind.J.Chem.*, 2004, **43B**, 184.
- 6 Swamy S N, Basappa B S, Prabhuswamy P B, Doreswamy B H, Prasad J S and Rangappa K S, *European journal of Med. Chem.*, 2006, **41**, 531.
- 7 Wang Z, You T, Yu Xu Haijian and Haoxin S *Molecules*, 1996, **1**, 68.
- 8 Udupi R H, Kushnoor A and Bhat A R, *J. Ind. Chem. Soc.*, 1999, **76**, 461.
- 9 Gupta R, Sudan S and Kachroo P L, *Ind. J. Chem.*, 1984, **23B**, 793.
- 10 Gupta R, Satya Paul, Gupta A K, Kachroo P L and Bani S *Ind. J. Chem.*, 1998, **37B**, 498.
- 11 Hirpara H M, Sodha V A, Trivedi A M, Khatri B L and Parikh A R *Ind. J. Chem.*, 2003, **42B**, 1756.
- 12 Joshi K C and Giri S, *J. Ind. Chem. Soc.*, 1963, **40**, 42.
- 13 Haglind J. *Chemical Abstract*, 1966, **64**,16509.
- 14 Reid J R and Heindel N D, *J. Heterocycl. Chem.*, 1976, **13**, 925.
- 15 Winter C A, Risley E A and Nuss G W, *Proc. Soc. Exp. Biol. Med.*, 1962, **111**, 544.
- 16 Kulkarni S K *Handbook of Experimental Pharmacology*; Vallabh Publications, 1999, 3rd Ed., 128.
- 17 Eddy N B and Leimbach D J, *J. Pharmacol. Exptl. Therap.*, 1953, 385.
- 18 Verma R S and Imam S A, *Ind. J. Microbiol.*, 1973,**13**,45.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

